paclitaxel has been researched along with Neutropenia in 683 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.15) | 18.7374 |
| 1990's | 204 (29.87) | 18.2507 |
| 2000's | 313 (45.83) | 29.6817 |
| 2010's | 136 (19.91) | 24.3611 |
| 2020's | 29 (4.25) | 2.80 |
| Authors | Studies |
|---|---|
| Atkins, AS; Burgett, AW; Harran, PG; McKnight, SL; Wang, X; Williams, NS | 1 |
| Cao, J; Gong, C; Hu, S; Hu, X; Li, T; Li, Y; Tao, Z; Wang, B; Wang, L; Xie, Y; Zhang, J; Zhao, Y | 1 |
| Hong, TH; Kim, H; Lee, MA; Park, SJ; Shin, K; Suh, JH | 1 |
| Hikita, K; Honda, M; Iwamoto, H; Kawamoto, B; Morizane, S; Shimizu, R; Takenaka, A; Teraoka, S; Yamaguchi, N; Yumioka, T | 1 |
| Huang, Q; Li, J; Li, L; Liu, D; Wang, Q; Wu, H; Ye, M; Yu, Z; Zeng, J; Zhang, J | 1 |
| Fukuda, S; Fukumitsu, K; Horiuchi, M; Ito, Y; Kagawa, Y; Kanemitsu, Y; Maeno, K; Mori, Y; Niimi, A; Oguri, T; Ohkubo, H; Sone, K; Suzuki, Y; Tajiri, T; Takemura, M; Toda, S; Uemura, T; Yamamoto, S | 1 |
| Fang, W; He, H; Hong, S; Huang, Y; Lin, Y; Lin, Z; Ma, Y; Salamone, SJ; Wu, Y; Xue, J; Yang, Y; Zhang, L; Zhang, Y; Zhao, H | 1 |
| Chen, R; Fan, L; Lei, L; Wang, X; Zheng, W | 1 |
| Aoyama, T; Chin, K; Hama, T; Kawaguchi, M; Kawakami, K; Takahari, D; Tomomatsu, T; Yamaguchi, K; Yamaguchi, M | 1 |
| Dong, Q; Du, F; Gao, L; Huo, X; Li, Z; Liu, Z; Ren, D; Shen, G; Wang, M; Xie, Q; Xin, Y; Zhao, F; Zhao, J; Zhao, Y | 1 |
| Asano, Y; Futamura, M; Hosono, Y; Ikawa, A; Ishihara, K; Katagiri, Y; Kawaguchi, Y; Kawajiri, M; Kitazawa, M; Kumazawa, I; Kuno, M; Matsuhasih, N; Mori, R; Morikawa, A; Mushika, Y; Nagao, Y; Nakada, T; Nakakami, A; Niwa, Y; Ogiso, A; Shimokawa, T; Takeuchi, M; Tokumaru, Y | 1 |
| Abe, M; Aida, T; Baba, T; Chiba, Y; Kagabu, M; Kaido, Y; Nagasawa, T; Shoji, T; Takahashi, F; Takatori, E | 1 |
| Akai, M; Anzai, M; Demura, Y; Honjo, C; Ishizuka, T; Nakashima, K; Ohi, M; Shimada, A; Sonoda, T; Tada, T; Umeda, Y; Waseda, Y; Yamaguchi, M | 1 |
| Abrams, TA; Biller, LH; Bollenrucher, N; Brais, LK; Cardot-Ruffino, V; Cleary, JM; Delius, L; Dougan, M; Dougan, SK; Enzinger, PC; Keheler, CE; McCleary, NJ; Ng, K; Patel, AK; Perez, K; Remland, J; Rubinson, DA; Schlechter, B; Singh, H; Slater, S; Sullivan, KM; Wang, SJ; Wolpin, BM; Yurgelun, MB | 1 |
| Beijnen, JH; Crombag, MBS; Dorlo, TPC; Huitema, ADR; Joerger, M; Koolen, SLW; Mathijssen, RHJ; van Erp, NP; Wijngaard, S | 1 |
| Ang, JE; Arkenau, HT; Beijnen, JH; Brunetto, AT; de Bono, JS; De Grève, J; de Jonge, MJA; Jager, A; Lolkema, MP; Marchetti, S; Mergui-Roelvink, MWJ; Schellens, JHM; Tchakov, I; van der Biessen, DA; van der Noll, R | 1 |
| Chen, T; Chen, Y; Chen, Z; Cheng, N; Hu, Y; Hu, Z; Liu, D; Liu, Y; Wang, C; Wang, Z; Xu, Y; Yan, G; Yao, S; Zhang, T; Zhao, G | 1 |
| Kim, S; Kim, SW; Kim, YN; Kim, YT; Lee, JY; Lee, YJ; Nam, EJ | 1 |
| Aieta, M; Chiriacò, G; Conca, R; Corona, SP; D'Angelo, A; Multari, AG; Paganini, G; Petrioli, R; Rosellini, P; Roviello, G | 1 |
| Fukushima, T; Hashimoto, Y; Hirotani, A; Ikeda, M; Imaoka, H; Kobayashi, S; Mitsunaga, S; Morimoto, M; Moriya, S; Ohno, I; Ozaka, M; Sano, Y; Sasahira, N; Sasaki, M; Sasaki, T; Tezuka, S; Tozuka, Y; Ueno, M; Umemoto, K; Watanabe, K; Yamada, I | 1 |
| Assefa, M; Gadisa, DA; Wang, SH; Yimer, G | 1 |
| Eguchi, H; Goda, K; Hashimoto, Y; Ikeda, M; Imaoka, H; Kan, M; Kimura, G; Mitsunaga, S; Ohno, I; Otsuru, T; Sasaki, M; Suzuki, Y; Takahashi, H; Umemoto, K; Watanabe, K | 1 |
| Catalano, M; Conca, R; D'Angelo, A; Ianza, A; Mini, E; Nobili, S; Palmieri, VE; Panella, B; Petrioli, R; Ramello, M; Roviello, G | 1 |
| Kobayashi, M; Komatsu, Y; Saito, Y; Sugawara, M; Takekuma, Y | 1 |
| Boras, B; Chen, W; D'Argenio, DZ; Hu, W; Spilker, ME; Sung, T | 2 |
| Aieta, M; Catalano, M; Conca, R; D'Angelo, A; Dreoni, L; Gasperoni, S; Ianza, A; Mini, E; Nobili, S; Petrioli, R; Ramello, M; Roviello, G | 1 |
| de Wiljes, J; Hartung, N; Huisinga, W; Kloft, C; Maier, C | 1 |
| Guo, M; Zhou, Q; Zou, D | 1 |
| Hayuka, K; Murakami, A; Nishiuchi, T; Okano, K; Okita, Y; Okuyama, H; Suzuki, Y; Tsuji, A | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Ido, A; Kawahira, M; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Fang, M; Jia, Y; Li, J; Liang, X; Luo, L; Lv, S; Song, T; Xu, H | 1 |
| Hazama, S; Inoue, Y; Kanekiyo, S; Kubo, H; Maeda, N; Matsui, H; Nagano, H; Nagashima, Y; Oka, M; Sakamoto, K; Sato, Y; Shindo, Y; Suzuki, N; Takeda, S; Ueno, T; Yamamoto, S; Yoshino, S | 1 |
| Eadens, M; Erlichman, C; Goetz, MP; Haddad, T; Lupu, R; Molina, J; Qin, R; Satele, D | 1 |
| Mahdi, H; Maurer, K; Michener, C; Rose, PG | 1 |
| Crim, A; Ding, K; Dvorak, J; Gillen, J; Greenwade, M; Gunderson, C; Moore, K; Rowland, M; Ruskin, R; Walter, A | 1 |
| Apte, SM; Chon, HS; Kang, S; Lee, JK; Shahzad, MM; Wenham, RM; Williams-Elson, I | 1 |
| Ahn, MJ; Barlesi, F; Fadeeva, N; Ganea, DE; Gonzalez Mella, PF; Govindan, R; Han, B; Jassem, J; Kopit, J; Kurata, T; Lee, KH; Li, M; O'Byrne, K; Postmus, PE; Reck, M; Schneider, CP; Szczesna, A; Tamura, T; Tschaika, M; Vladimirov, V; Von Pawel, J; Zhang, L | 1 |
| Chen, S; Chen, Y; Hu, Y; Jiao, S; Li, J; Yan, X; Zhang, G; Zhang, Y | 1 |
| Christofillakis, C; Georgoulias, V; Kalbakis, K; Kentepozidis, N; Kourousis, C; Mavroudis, D; Nikolaou, M; Pistamaltzian, N; Polyzos, A; Saloustros, E; Vamvakas, L | 1 |
| Ishikawa, M; Kagawa, Y; Kawai, M; Maeda, T | 1 |
| Allan, E; Ayan, A; Barney, CL; Bazan, JG; DiCostanzo, D; Grecula, J; Haglund, KE; Otterson, GA; Scoville, N; Williams, T; Xu-Welliver, M | 1 |
| Chen, C; Chen, ZS; Fang, L; Huang, HQ; Li, CZ; Lin, LF; Qiu, GD; She, YQ; Xin, DS; Zhang, SQ; Zhang, SY; Zheng, JT; Zhou, L | 1 |
| Chenel, M; Fouliard, S; Friberg, LE; Hooker, AC; Karlsson, MO; Pierrillas, PB | 1 |
| Adachi, S; Asano, H; Ito, D; Iwai, M; Kimura, M; Matsuo, K; Okada, K; Teramachi, H; Usami, E; Yoshimura, T | 1 |
| Hira, D; Ikeda, Y; Katsube, Y; Koide, H; Minegaki, T; Morita, SY; Nishiguchi, K; Terada, T; Tsujimoto, M | 1 |
| Fujita, M; Hirano, R; Igata, F; Ikeda, T; Imabayashi, T; Kaneko, Y; Kishimoto, J; Nagata, N; Nakao, A; On, R; Sasaki, T; Takayama, K; Tamiya, N; Tanimura, K; Uchino, J; Watanabe, K; Yamada, T; Yatsugi, H | 1 |
| An, C; Bang, S; Cho, IR; Chung, JB; Chung, MJ; Jo, JH; Jung, SY; Kang, H; Lee, HS; Park, JY; Park, MS; Park, SW; Song, SY | 1 |
| Chen, YH; Huang, ST; Li, WS; Lin, CT; Wang, YP; Wu, HC | 1 |
| Abe, M; Chiba, T; Iino, Y; Kato, N; Mikata, R; Ogawa, Y; Ohyama, H; Suzuki, E; Tsuyuguchi, T; Yasui, S | 1 |
| Chen, QY; Guo, L; Guo, SS; Li, XY; Liang, YJ; Lin, C; Lin, HX; Liu, LT; Liu, SL; Mai, HQ; Sun, XS; Tang, LQ; Tang, QN; Wen, YF; Xie, HJ; Yan, JJ; Yang, ZC | 1 |
| Blomstrand, H; Bratthäll, C; Elander, NO; Green, H; Scheibling, U | 1 |
| Goodwin, A; O'Connell, DL; Wilcken, N; Willson, ML; Zaheed, M | 1 |
| Funakoshi, T; Hirai, I; Ishii, M; Kawakami, Y; Nakamura, Y; Tanese, K | 1 |
| Arenare, L; Attademo, L; Breda, E; Cardalesi, C; Cecere, SC; Cognetti, F; Cormio, G; Daniele, G; De Placido, S; Ferrandina, G; Ferro, A; Gallo, C; Guizzaro, L; Lorusso, D; Marsico, VA; Panici, PB; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Rimanti, A; Salutari, V; Savarese, A; Scalone, S; Scambia, G; Schettino, C; Sorio, R | 1 |
| Harada, D; Kageyama, A; Kawakubo, T; Kitamura, M; Mitsumori, N; Nakazawa, Y | 1 |
| Inokuchi, T; Kuga, T; Nakamura, T; Sano, F; Tanaka, Y; Yano, Y | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R | 1 |
| Blohmer, JU; Costa, SD; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Höß, C; Huober, J; Jackisch, C; Khandan, F; Kittel, K; Krabisch, P; Kümmel, S; Loibl, S; Mau, C; Minckwitz, Gv; Nekljudova, V; Rezai, M; Schwedler, K; Tesch, H; Untch, M | 1 |
| Kashiwabara, K; Tanaka, H; Yamane, H | 1 |
| Abaid, LN; Brown, JV; Goldstein, BH; Lopez, KL; Mendivil, AA; Micha, JP; Rettenmaier, MA | 1 |
| Alva, A; Daignault-Newton, S; Grivas, PD; Hafez, K; Hollenbeck, B; Hussain, M; Lee, CT; Montgomery, JS; Montie, JE; Smith, DC; Weizer, A; Wood, D | 1 |
| Bigay-Game, L; Braun, D; David, P; Debieuvre, D; Depierre, A; Douillard, JY; Laporte, S; Lavolé, A; Lebeau, B; Lemarié, E; Milleron, B; Molinier, O; Morin, F; Ozenne, G; Poudenx, M; Pujol, JL; Puyraveau, M; Quoix, E; Rivière, A; Westeel, V; Zalcman, G | 1 |
| Jarboe, J; Saif, MW | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Freudensprung, U; Gladieff, L; Gonzalez-Martin, A; Gore, M; Kovalenko, N; Oaknin, A; Pignata, S; Ronco, JP; Scambia, G; Stroyakovsky, D; Tholander, B | 1 |
| Arena, FP; Bahary, N; Chiorean, EG; Dowden, S; Ervin, T; Goldstein, D; Harris, M; Hidalgo, M; Iglesias, J; Infante, J; Laheru, D; Ma, WW; Moore, M; Ramanathan, RK; Reni, M; Renschler, MF; Saleh, MN; Seay, T; Tabernero, J; Tjulandin, SA; Van Cutsem, E; Von Hoff, DD; Wei, X | 1 |
| Beckman, RA; Chmielowska, E; Fox, T; Greenberg, J; Hadler, D; Krzakowski, M; Reck, M; Sebastian, M; von Pawel, J; Wang, Q | 1 |
| Boku, N; Esaki, T; Fujitani, K; Hamamoto, Y; Hironaka, S; Hyodo, I; Morita, S; Moriwaki, T; Nagase, M; Nishina, T; Okamoto, I; Shimodaira, H; Sugimoto, N; Tokunaga, S; Tsuda, M; Tsumura, T; Ueda, S; Ura, T; Yamaguchi, K; Yasui, H | 1 |
| Bycott, P; Chen, C; Chmielowska, E; de Besi, P; Havel, L; Ingrosso, A; Kim, S; Olszanski, AJ; Popat, S; Sawrycki, P; Schiller, JH; Swieboda-Sadlej, A; Twelves, C; Williams, JA | 1 |
| Chen, L; Chen, Q; Chen, Z; Shen, L; Shen, X; Tao, J; Wang, H; Wang, J; Zhang, Y; Zhu, M; Zhuang, Z | 1 |
| Bookman, MA; Gatcliffe, TA; Java, JJ; Monk, BJ; Tewari, KS | 1 |
| Goto, M; Hara, T; Koizumi, W; Miyata, Y; Muro, K; Nishina, T; Sasaki, Y; Toh, Y; Tsuji, A; Yasui, H | 1 |
| Chen, N; Chopra, R; Li, Y; Palmisano, M; Ye, Y; Zhou, S | 1 |
| Ando, M; Aogi, K; Fujiwara, Y; Hamano, T; Inoue, K; Iwata, H; Kuroi, K; Masuda, N; Ohono, S; Shimizu, S; Sukigara, T; Yamamoto, N; Yamauchi, H | 1 |
| An, SM; Badakhshi, H; Chen, Y; Deng, JY; Guo, XM; Jiang, GL; Ma, HF; Tang, HR; Zhang, JH; Zhang, Z; Zhao, KL | 1 |
| Cao, Y; Gong, J; Li, J; Li, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Wu, Y; Zhang, X; Zhou, J | 1 |
| Chen, J; Chen, M; Li, J; Lin, Y; Liu, J; Pan, C; Pan, J; Zhu, K | 1 |
| Doerr, M; Kim, J; Kitchell, BE | 1 |
| Conte, M; Ellingrod, VL; King, AN; O'Malley, M; Ramnath, N | 1 |
| Buyse, M; Fukushima, R; Hara, A; Imamura, H; Kobayashi, M; Kojima, H; Miyashita, Y; Morita, S; Nishikawa, K; Nozaki, I; Oba, K; Sakamoto, J; Takahashi, M; Takahashi, N; Takiguchi, N; Tanabe, K; Tatsumoto, N; Tsuburaya, A; Yoshida, K; Yoshino, S | 1 |
| Fang, W; Jiang, H; Mao, C; Qian, J; Xu, N; Zhang, X; Zhao, P; Zheng, Y | 1 |
| Bratos, R; Colomer, R; Escudero, MJ; Gil, M; Gil-Martin, M; Gonzalez-Martin, A; Guerra, J; Hernandez-Agudo, E; Hilberg, F; Marquez, R; Quintela-Fandino, M; Rodriguez-Martin, C; Urruticoechea, A; Vlassak, S | 1 |
| Bellon, JR; Berry, DA; Carey, LA; Cirrincione, CT; Collyar, D; Golshan, M; Hahn, OM; Hudis, CA; Kuzma, CS; Perou, CM; Pluard, TJ; Port, ER; Sikov, WM; Singh, B; Somlo, G; Tolaney, SM; Winer, EP | 1 |
| Boere, IA; de Gooyer, D; Goey, SH; Kerkhofs, LG; Kok, TC; Look, M; Onstenk, W; Ottevanger, PB; Ruit, JB; ten Bokkel Huinink, D; Valster, FA; van der Burg, ME; van der Torren, AM; van Doorn, HC; van Reisen, AG; Verweij, J | 1 |
| Fujiwara, K; Hanaoka, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T | 1 |
| Du, J; Hu, B; Hu, C; Wang, F; Zhang, Y | 1 |
| Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nagashima, K; Nishikawa, A; Okita, N; Sasaki, Y; Sawada, R; Shimada, Y; Shirakawa, T; Shoji, H; Takahashi, N; Takashima, A; Yamada, Y | 1 |
| Fridley, BL; Ghosh, TM; Gupta, P; Lamba, JK; Mehta, G; Yu, Q | 1 |
| Chen, F; Chen, Y; Cheng, B; Fang, Y; Qu, X; Wang, Z; Xiong, B | 1 |
| Chau, I; Smyth, EC; Tarazona, N | 1 |
| Bae, KS; Hong, YS; Hwang, AK; Jo, YW; Jung, JA; Kang, YK; Kim, JE; Kim, K; Kim, TW; Lee, JL; Lim, HS; Noh, YH; Park, SJ | 1 |
| Amani, M; Broucek, M; Monga, V; Ramaswamy, S | 1 |
| Akcakanat, A; Chen, H; Culotta, KS; Do, KA; Doyle, LA; Gonzalez-Angulo, AM; Krop, I; Kurzrock, R; Li, Y; Liu, S; Meric-Bernstam, F; Mills, GB; Moulder-Thompson, S; Piha-Paul, S; Sahin, AA; Tarco, E; Velez-Bravo, V; Winer, EP | 1 |
| Jaehde, U; Joerger, M; Kraff, S; Lindauer, A; Salamone, SJ | 1 |
| Ding, W; Li, J; Li, Y; Wang, X | 1 |
| Amant, F; Berteloot, P; D'Hondt, L; Debruyne, P; Forget, F; Geldhof, K; Honhon, B; Huizing, M; Kridelka, F; Laenen, A; Leunen, K; Lybaert, W; Van den Bulck, H; Vergote, I; Verhoeven, D; Vuylsteke, P | 1 |
| Gomez, D; Komaki, R; Lee, MS; Levy, LB; Liao, Z; Lu, C; Tang, C; Zhuang, Y | 1 |
| Fang, J; Liu, LF; Wu, MJ; Yin, ZM; Yu, AJ; Yu, H; Zhu, JQ | 1 |
| de Bruijn, P; de Graan, AJ; Elbouazzaoui, S; Martens, JW; Mathijssen, RH; Nieuweboer, AJ; Smid, M; van Schaik, RH | 1 |
| Hao, X; Li, C; Su, W; Zhang, J; Zhang, S | 1 |
| Bidziński, M; Bjørge, L; Colombo, N; de Gregorio, N; Del Campo, JM; Denison, U; du Bois, A; Harter, P; Heubner, M; Hilpert, F; Kristensen, G; Lortholary, A; Malander, S; Meier, W; Merger, M; Minarik, T; Mirza, MR; Nicoletto, MO; Ottevanger, P; Pfisterer, J; Pignata, S; Ray-Coquard, I; Reuss, A; Sailer, MO; Scambia, G; Sevin, E; Vergote, I | 1 |
| Hara, F; Hozumi, Y; Imoto, S; Matsubara, N; Mukai, H; Nishimura, R; Ohashi, Y; Park, Y; Sagara, Y; Saito, T; Shimozuma, K; Takano, T; Takashima, T; Toyama, T; Tsurutani, J; Watanabe, T | 1 |
| Ahmed, I; Aisner, J; Benenati, B; Chen, T; Deek, MP; Jabbour, SK; Kim, S; Zou, W | 1 |
| Adam, J; Bastien, B; Beck, JT; Chouaid, C; Debieuvre, D; Felip, E; Forget, F; Gervais, R; Halluard, C; Kazarnowicz, A; Lacoste, G; Lena, H; Limacher, JM; Losonczy, G; Madroszyk, A; Ottensmeier, C; Palanché, T; Papai, Z; Quoix, E; Szczesna, A; Tavernaro, A; Westeel, V | 1 |
| Alsharedi, M; Dotson, J; Elmsherghi, N; Gress, T; Tirona, MT | 1 |
| Imamura, F; Ishitobi, M; Kittaka, N; Nakayama, T; Okuno, J; Sugimoto, N; Tamaki, Y; Yagi, T; Yoshinami, T | 1 |
| Couture, F; Dowden, S; El-Maraghi, R; Kennecke, H; Lesperance, B; Letourneau, R; Liu, H; Romano, A; Tehfe, M | 1 |
| Fujii, N; Inoue, R; Kobayashi, K; Matsumoto, H; Matsuyama, H; Nagao, K; Shimizu, K; Yamamoto, Y | 1 |
| Jiang, YX; Li, YH; Liang, Y; Luo, HY; Wang, DS; Wang, FH; Wang, Y; Wang, ZQ | 1 |
| Endo, H; Katayama, K; Takahashi, Y; Tanaka, T | 1 |
| Copur, MS; DeSpiegelaere, H; Ganti, AK; Huerter, MM; Kessinger, A; Ketcham, M; Kos, ME; Kruse, S; Marr, AS; Meza, JL; Radniecki, SE; Swenson, K; Tolentino, A | 1 |
| Dezentjé, VO; Honkoop, AH; Kemper, I; Linn, SC; Mandjes, IA; Oving, IM; Smorenburg, CH; Sonke, GS; Stouthard, JM; van Ramshorst, MS; van Werkhoven, E | 1 |
| Barroso-Sousa, R; Batista, RB; Bunnell, CA; Camuso, K; Costa, RB; Golshan, M; Hughes, ME; Lin, NU; Losk, K; Metzger-Filho, O; Paes, FR; Vaz-Luis, I; Winer, EP | 1 |
| Altundag, K; Barnadas, A; Botha, M; Chan, A; Cinieri, S; Coskun, U; Dodyk, P; Lazzarelli, S; Rauch, D; Tubiana-Mathieu, N; Vandebroek, A; Villanova, G | 1 |
| Shen, K; Wu, J; Zong, Y | 1 |
| Hayami, S; Hirono, S; Kawai, M; Kitahata, Y; Miyazawa, M; Okada, KI; Shimizu, A; Ueno, M; Yamaue, H | 1 |
| Seagle, BL; Shahabi, S | 1 |
| Arnold, RD; Awada, A; Bulitta, JB; Daifuku, R; Gelderblom, H; Hanauske, AR; Jusko, WJ; Kessler, DR; Luciano, G; Pratt, J; Zhao, P | 1 |
| Damjanov, N; Dul, JL; Fetterly, GJ; Fiedler-Kelly, J; Fishman, M; Grahn, A; Grasela, TH; Kane, MP; Lecomte, D; Rubin, EH; Sherman, JW; Tan, AR | 1 |
| Kamiyama, Y; Kano, Y; Kobayashi, H; Kodama, T; Mori, K | 1 |
| Ilson, DH; Kelsen, DP; Kepler, S; O'Reilly, E; Radovich, D; Saltz, LB; Schrag, D; Schwartz, G; Tew, WP | 1 |
| Cai, RG; Li, Q; Wang, JY; Wu, WH; Xu, BH; Yuan, P; Zhang, P; Zhao, LM; Zhou, AP | 1 |
| Kendrick, JE; Kilgore, LC; Matthews, KS; Numnum, TM; Shipman, KA; Straughn, JM; Whitworth, JM | 1 |
| Gennatas, K; Gennatas, S; Michalaki, V | 1 |
| Ando, M; Fujiwara, Y; Iura, A; Katsumata, N; Kouno, T; Shimizu, C | 1 |
| Altieri, V; Autorino, R; Cartenì, G; De Placido, S; Di Lorenzo, G; Doria, F; Faiella, A; Ferro, M; Gonnella, A; Imbimbo, C; Longo, N; Mirone, V; Palmieri, G; Perdonà, S; Rescigno, P | 1 |
| Liu, C; Shen, W; Sun, Q; Wang, D; Xu, H; Zhong, B; Zhong, H | 1 |
| Fukuoka, M; Nakagawa, K; Saijo, N; Sekine, I; Takada, M; Tanigawara, Y; Yamamoto, N | 1 |
| Alonso, S; Calabrò, F; Di Paula, ED; Frassineti, L; Lorusso, V; Manzione, L; Rosati, G; Sava, T; Sternberg, CN | 1 |
| Georgoulias, V; Kotsakis, A; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P; Saridaki, Z; Souglakos, J; Vardakis, N | 1 |
| Coltman, CA; Crowley, J; Fukuoka, M; Fukushima, M; Furuse, K; Gandara, DR; Gautschi, O; Kawaguchi, T; Kawahara, M; Kubota, K; Lara, PN; Lenz, HJ; Mack, PC; McLeod, HL; Moon, J; Ohe, Y; Saijo, N; Teramukai, S; Williamson, SK | 1 |
| Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Lee, SJ; Shim, HJ; Yoon, JY | 1 |
| Honova, H; Kralova, D; Pazdro, A; Pazdrova, G; Petruzelka, L; Smejkal, M; Zemanova, M | 1 |
| Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Mahoney, SL; Papadopoulos, NE | 1 |
| Avallone, A; Chiuri, VE; Cioffi, R; Comella, P; Costanzo, R; De Cataldis, G; Filippelli, G; Franco, L; Greco, E; Maiorino, L; Mancarella, S; Palmeri, L; Putzu, C; Vessia, G | 1 |
| Camidge, DR; Chow, LQ; Cohen, RB; Diab, S; Eckhardt, SG; Fox, NL; Gore, L; Gustafson, DL; Hariharan, S; Langer, CJ; Leong, S; Miceli, R; O'Bryant, C; Padavic, K; Smith, M; von Mehren, M | 1 |
| Ballardini, M; Carpi, A; Conte, P; Favalli, G; Gadducci, A; Katsaros, D; Nanni, O; Panici, PB; Pecorelli, S; Scambia, G | 1 |
| Benda, J; Boardman, CH; Cella, D; Cohn, DE; McMeekin, DS; Monk, BJ; Ramondetta, LM; Sill, MW | 1 |
| Dizon, DS; Fenton, MA; Gass, JS; Graves, TA; Kennedy, TA; Legare, RD; Sikov, WM; Strenger, R; Theall, KP | 1 |
| Hatta, M; Kamigaki, S; Masuda, N; Nakayama, T; Sakamoto, J; Taguchi, T; Yamamura, J | 1 |
| Bekaii-Saab, T; Byrd, JC; Culler, K; Grever, MR; Lesinski, GB; Lucas, DM; Ramaswamy, B; Ruppert, AS; Schaaf, LJ; Shapiro, CL; Wilkins, D; Wright, JJ; Young, DC | 1 |
| Harrold, JM; Mager, DE; Mazurchuk, RV; Straubinger, RM; Tamburlin, JH; Zhou, R | 1 |
| Chang, H; Choi, HJ; Chung, HC; Kim, JH; Kim, SI; Kim, YT; Koo, JS; Moon, YW; Park, BW; Park, S; Roh, JK; Sohn, JH | 1 |
| Bekele, NB; Carter, CM; Mathew, P; Pagliaro, L; Tannir, N; Tu, SM | 1 |
| Liu, SP; Wang, XE; Zhang, MQ | 1 |
| Kim, DY; Kim, JH; Kim, JJ; Kim, YM; Kim, YT; Nam, JH; Park, JY | 1 |
| Ito, S; Kawai, H; Matsuo, K; Muro, K; Sawaki, A; Shibata, T; Shitara, K; Tajika, M; Takahari, D; Ura, T; Yokota, T | 1 |
| Aguiló, R; Alberola, V; Alonso, G; Astudillo, J; Borro, JM; Camps, C; Felip, E; González-Larriba, JL; Guijarro, R; Hermosilla, E; Isla, D; Maestre, JA; Massuti, B; Morán, T; Padilla, J; Rodríguez-Paniagua, JM; Rosell, R; Sánchez, JJ; Sánchez-Palencia, A; Torres, A | 1 |
| Borgato, L; Donach, ME; Furini, L; Lombardi, G; Nicoletto, MO; Palma, MD; Zustovich, F | 1 |
| Abaid, LN; Brown, JV; Goldstein, BH; Markman, M; Micha, JP; Rettenmaier, MA | 1 |
| Billaud, EM; Bobin-Dubigeon, C; Boisdron-Celle, M; Boyer, JC; Chatelut, E; Concordet, D; Durdux, C; Etienne-Grimaldi, MC; Evrard, A; Floquet, A; Gladieff, L; Laffont, CM; Lafont, T; Lansiaux, A; Le Guellec, C; Mazières, J; Mousseau, M; Ollivier, F; Pinguet, F; Schmitt, A | 1 |
| Conrad, B; Forstbauer, H; Koehne, CH; Kremers, S; Linder, M; Loibl, S; Moebus, V; Mueller, V; Nekljudova, V; von Minckwitz, G | 1 |
| Li, XR; Liao, N; Wang, K; Yao, M; Zhang, GC; Zu, J | 1 |
| Fukuda, M; Kasai, T; Kinoshita, A; Kohno, S; Masuda, N; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsukamoto, K | 1 |
| Ando, M; Fukuoka, M; Iwamoto, Y; Katakami, N; Kurata, T; Maeda, M; Nakagawa, K; Nakano, T; Saito, H; Takeda, K | 1 |
| Hara, T; Nishikawa, K; Oba, K; Omura, K; Sakamoto, J; Sakatoku, M | 1 |
| Goto, H; Haruta, J; Ina, K; Iwase, H; Kumada, T; Shimada, M; Shinoda, M; Sugihara, M; Tsuzuki, T | 1 |
| Åvall-Lundqvist, E; Gréen, H; Jakobsen-Falk, I; Khan, MS; Peterson, C | 1 |
| Bidoli, E; Capobianco, G; Dessole, F; Lombardi, D; Miolo, G; Santeufemia, DA; Scalone, S; Sorio, R; Spazzapan, S; Tabaro, G; Veronesi, A | 1 |
| Bari, M; Ciruelos, E; De Benedictis, E; Dittrich, C; Gaion, F; Gomez, P; Lluch, A; Luca, G; Mansutti, M; Morandi, P; Pavesi, L; Semiglazov, V; Valagussa, P; Zamagni, C; Zambetti, M | 1 |
| Aghajanian, CA; Berlin, S; Hensley, ML; Iasonos, A; Jia, X; Kravetz, S; Pereira, L; Sabbatini, P; Tew, W; Whalen, C; Zarwan, C | 1 |
| Chiba, Y; Fukuda, H; Fukuoka, M; Kokubo, M; Kudoh, S; Nakagawa, K; Nakanishi, Y; Negoro, S; Nishimura, Y; Tada, T; Tsujino, K | 1 |
| Choong, N; Firat, S; Kharofa, J; Sadasiwan, C; Schultz, C; Wang, D; Wong, S | 1 |
| Orlova, RV; Protasova, AE | 1 |
| Bouchard, D; Brenner, A; Chandhasin, C; Elian, K; Gabrail, N; Kurzrock, R; Mita, A; Moulder, S; Sankhala, K; Sarantopoulos, J; Smith, C | 1 |
| Huang, XE; Li, CG; Li, Y; Lu, YY; Tang, JH; Xiang, J | 1 |
| Jin, ZL; Li, K; Li, N; Liu, ZJ; Wang, J | 1 |
| Barron, R; Edelsberg, J; Kartashov, A; Lyman, G; Weycker, D | 1 |
| Bellmunt, J; Boehle, A; Chevreau, C; Collette, S; Daugaard, G; De Santis, M; de Wit, R; Laufman, LR; Marreaud, S; Mead, GM; Paz-Ares, L; Raghavan, D; Skoneczna, I; Sylvester, R; von der Maase, H; Winquist, E | 1 |
| Koroleva, IA; Mochalova, AS | 1 |
| Bi, N; Cao, J; Li, J; Li, W; Liang, J; Lv, J; Ou, G; Ren, H; Wang, L; Wu, S; Zhang, X; Zhou, Z | 1 |
| Cariello, A; Casanova, C; Cruciani, G; Dazzi, C; Freier, E; Gamboni, A; Leoni, M; Mazza, V; Milandri, C; Montanari, M; Papi, M; Papiani, G; Verlicchi, A; Vertogen, B | 1 |
| Ait-Oudhia, S; Mager, DE; Straubinger, RM | 1 |
| Arakawa, A; Furukawa, N; Hirashima, Y; Itani, Y; Ito, K; Murakoshi, H; Tabata, T; Takekuma, M; Takeuchi, S; Tsubamoto, H | 1 |
| Coulon Sfairi, MA; Dalenc, F; Delva, R; Espié, M; Hardy-Bessard, AC; Kockler, L; Lortholary, A; Monnier, A; Pavlyuk, M; Pierga, JY; Pivot, X; Serin, D; Veyret, C | 1 |
| Beijnen, JH; Feiss, G; Huitema, AD; Jaehde, U; Joerger, M; Kraff, S; Moritz, B; Schellens, JH | 1 |
| Kang, S; Lim, MC; Lim, S; Park, JY; Park, SY; Seo, SS; Yoo, HJ | 1 |
| Beumer, JH; Cotarla, I; Deeken, J; Egorin, MJ; Elston, B; Firozvi, K; Hartley, ML; He, AR; Hwang, J; Koh, EY; Liu, M; Malik, S; Marshall, JL; Pishvaian, MJ; Slack, R; Strychor, S | 1 |
| Arias-Pulido, H; Bauman, JE; Carr, LL; Cerilli, LA; Eaton, KD; Jones, DV; Lee, SJ; Martins, RG; Wallace, SG | 1 |
| Dakhil, SR; Hirsh, V; Hon, JK; Langer, CJ; Okamoto, I; Orsini, J; Page, RD; Renschler, MF; Socinski, MA; Zhang, H | 1 |
| Bustam, AZ; Ng, CH; Phua, CE; Saad, M; Taib, NA; Teh, YC; Yip, CH; Yusof, MM | 1 |
| Allred, JB; Fitch, TR; Hobday, TJ; Liu, H; Lyss, AP; Northfelt, DW; Perez, EA; Rodacker, MW | 1 |
| Fujitani, K; Furukawa, H; Imamura, H; Imano, M; Kimura, Y; Kurokawa, Y; Matsuoka, M; Shimokawa, T; Takiuchi, H; Tokunaga, Y; Tsujinaka, T; Yano, H | 1 |
| Boere, IA; Leunen, K; Onstenk, W; van der Burg, ME; van Doorn, HC; van Montfort, CA; Vergote, I | 1 |
| Cai, RG; Fan, Y; Ma, F; Ma, WY; Wang, JY; Wang, X; Xu, BH; Xu, XZ; Yuan, P; Zhang, BL; Zhang, P; Zheng, S | 1 |
| Brassard, M; Budman, DR; Cohen, G; Dhami, M; George, T; Glaspy, J; Hackett, J; Holmes, FA; Jones, SE; Liang, BC; Meza, L; O'Shaughnessy, J; Richards, D; Savin, M; Vukelja, S; Yang, BB | 1 |
| Fife, K; Ganjoo, KN; Gordon, MS; Loehrer, PJ; Poirier, S; Sandler, AB; Seshadri, R; Warner, RE | 1 |
| Tsukuda, M | 1 |
| Degendorfer, P; Furlan, M; McCarthy, JS; Panzarella, T; Siu, LL; Tannock, IF | 1 |
| Gnant, MF; Jakesz, R; Locker, GJ; Oberhuber, G; Pluschnig, U; Rudas, M; Steger, GG; Taucher, S; Wenzel, C; Zielinski, CC | 1 |
| Baselga, J; Bellmunt, J; Clèries, R; Cos, J; Eres, N; Margarit, C; Murio, JE; Pérez, M; Ribas, A | 1 |
| Asmar, L; Cox, E; Dakhil, S; Gregurich, MA; Loesch, D; O'Rourke, M; Robert, N | 1 |
| Calvert, H; Calvert, P; Gallant, G; Ghielmini, M; Gupta, E; Plummer, R; Renard, J; Sessa, C; Voi, M | 1 |
| Antonellini, A; Elfring, GL; Gillenwater, HH; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Sandler, AB; Socinski, MA | 1 |
| Bang, YJ; Boudraa, Y; Daglish, B; Heo, DS; Jacques, C; Kang, WK; Kang, YK; Kim, HC; Kim, NK; Kim, WS; Zuber, E | 1 |
| Ansari, R; Bhatia, S; Einhorn, L; Hanna, N; Ng, E; Pletcher, W; Sandler, A | 1 |
| Ansari, R; Bhatia, S; Einhorn, L; Hanna, N; Sandler, A | 1 |
| Borsellino, N; Cazzato, C; Colucci, G; Durini, E; Galetta, D; Gebbia, V; Giotta, F; Pezzella, G; Romito, S | 1 |
| Chang, WC; Chao, TY; Chen, CH; Hsu, JW; Lin, MC; Tsao, TC | 1 |
| Campos, B; Carrete, N; Constenla, M; Garcia-Arroyo, R; Lorenzo, I; Palacios, P | 1 |
| Chang, JY; Chen, LT; Chung, TR; Jan, CM; Liu, JM; Liu, TW; Shiah, HS; Whang-Peng, J; Wu, CW | 1 |
| Fukuoka, M; Inoue, A; Kunitoh, H; Mori, K; Nukiwa, T; Saijo, N | 1 |
| Adamo, V; Altavilla, G; Boni, C; Ceribelli, A; Clerici, M; Crinò, L; De Marinis, F; Di Costanzo, F; Failla, G; Frontini, L; Gridelli, C; Marangolo, M; Matano, E; Ricci, S; Rinaldi, M; Scagliotti, GV; Tonato, M | 1 |
| Cantin, J; Chang, J; Guevin, R; Lindsay, MA; Mackey, J; Nabholtz, JM; Patel, R; Reese, D; Riva, A; Tkaczuk, K; Vodvarka, P | 1 |
| Assadourian, S; Bonneterre, J; Fargeot, P; Guastalla, JP; Monnier, A; Namer, M; Roché, H | 1 |
| Balañá, C; Font, A; Guillot, M; Manzano, JL; Margelí, M; Richardet, M; Rosell, R; Sánchez, JJ; Sánchez, JM | 1 |
| Douillard, JY; Eckardt, J; Scagliotti, GV | 1 |
| Crawford, J | 1 |
| Baselga, J; Clemens, MR; Galid, A; Gascon, P; Green, MD; Guillem, V; Koelbl, H; Lalisang, RI; Liang, BC; Piccart, MJ; Renwick, J; Samonigg, H; Siena, S; Zani, V | 1 |
| Beijnen, JH; Boot, H; Kruijtzer, CM; Lochs, HL; Mathôt, RA; Parnis, FX; Pelgrims, JM; Planting, AS; Rosing, H; Schellens, JH; Schot, ME; Van Tinteren, H; Williams, R | 1 |
| Ashamalla, H; Colella, F; Krishnamurthy, M; Mokhtar, B; Ross, P; Selim, H; Zaki, B | 1 |
| Fujimura, M; Iwasa, K; Kasahara, K; Kimura, H; Myo, S; Nakao, S; Nishi, K; Shibata, K; Shintani, H; Shirasaki, H; Yasuda, U | 1 |
| Tuma, RS | 1 |
| Ando, M; Katsumata, N; Mukai, H; Watanabe, T | 1 |
| Birch, R; Campos, L; Hainsworth, J; Schnell, F; Tongol, J; West, W | 1 |
| Hiramatsu, Y; Hongo, A; Kodama, J; Kudo, T; Mizutani, Y; Nagao, S; Okimoto, N; Yoshinouchi, M | 1 |
| Markman, M | 1 |
| Haddad, R; Posner, M | 1 |
| al-Jazayrly, G; Edelman, MJ; Gandara, DR; Houston, J; Lara, PN; Lau, DH; Lauder, I; Lim, N; Tanaka, M | 1 |
| Allen, M; Bomphray, CC; Gore, ME; Hess, V; Vaughan, MM; Verrill, MW | 1 |
| Brockstein, BE; Mani, S; Masters, GA; Ratain, MJ | 1 |
| Abbasi, MR; Sarta, C; Sparano, JA; Wiernik, PH | 1 |
| Almanza, C; Amenedo, M; Gamazo, JL; Gómez-Martín, C; González-Ageitos, A; González-Quintas, A; Losada, G; Ramos, M; Romero, C; Togores, P | 1 |
| Arbuck, SG; Averette, HE; Brady, MF; Delmore, JE; Long, HJ; Look, KY; Omura, GA; Spiegel, G; Wadler, S | 1 |
| Flaherty, KT; Hahn, SM; O'Dwyer, PJ; Redlinger, M; Stevenson, JP | 1 |
| Blohmer, J; Kaubitzsch, S; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D | 1 |
| Bernstein, ML; Blaney, S; Hayashi, RJ; Sullivan, J; Vietti, T; Weitman, S | 1 |
| Airoldi, M; Bumma, C; Cattel, L; Marchionatti, S; Pedani, F; Recalenda, V; Tagini, V | 1 |
| Biamonte, R; Di Vagno, G; Ferrandina, G; Ferrau', F; Gadducci, A; Greggi, S; Lorusso, D; Manzione, L; Pignata, S; Scambia, G; Tateo, S | 1 |
| Aravantinos, G; Bafaloukos, D; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kosmidis, P; Papadimitriou, C; Pavlidis, N | 1 |
| Baioni, M; Ballardini, M; De Giorgi, U; Ferrari, E; Marangolo, M; Minzi, MR; Rosti, G; Zaniboni, A; Zornetta, L | 1 |
| Baselga, J; Carrato, A; Domine, M; Felip, E; Font, A; Garrido, P; Mañe, JM; Rosell, R; Santomé, L; Terrasa, J; Vadell, C | 1 |
| Bar-Sela, G; Gaitini, D; Haim, N; Steiner, M; Tsalic, M | 1 |
| Inoue, K; Kai, T; Koh, J; Mihara, H; Mochizuki, H; Okubo, K; Saito, T; Sato, K; Tabei, T | 1 |
| Belinson, J; Elson, P; Kulp, B; Markman, M; Peterson, G; Webster, K; Zanotti, K | 1 |
| Jennens, R; Millward, M; Rischin, D; Toner, G; Yuen, K | 1 |
| Chow, C; Cowan, KH; Cusack, G; Danforth, D; Eng-Wong, J; Kohler, DR; O'Shaughnessy, J; Riseberg, D; Venzon, D; Zujewski, JA | 1 |
| Allen, HJ; Baker, C; Bosserman, LD; Chapman, Y; Figlin, RA; Gitlitz, BJ; Patel, R; Sanchez, JD; Shapiro, RM | 1 |
| Chun, JH; Han, JY; Hong, EK; Kim, HY; Lee, DH; Lee, HG; Lee, JS; Lee, SY; Shin, EH; Yoon, SM | 1 |
| Hayman, JA; Ianettonni, M; Orringer, MB; Satoru, H; Urba, SG | 1 |
| Butts, JA; Greco, FA; Hainsworth, JD; Meluch, AA; Morrissey, LH; Raefsky, EL; Steis, RG | 1 |
| Dilek, TU; Guner, H; Oktem, M | 1 |
| Fujii, Y; Hara, Y; Iwase, H; Sugiura, H; Toyama, T; Yamashita, H | 1 |
| Dawson, NA; Edelman, MJ; Houston, J; Lara, PN; Lauder, I; Law, LY; Meyers, FJ | 1 |
| Bains, MS; Brenner, B; Gonen, M; Ilson, DH; Kelsen, DP; Minsky, BD; Tong, W | 1 |
| Hsu, Y; Sood, AK; Sorosky, JI | 1 |
| Belani, CP; Day, R; Jacobs, SA; Jett, JR; Ramalingam, S; Zamboni, BA | 1 |
| Belinson, J; Kulp, B; Markman, J; Markman, M; Peterson, G; Webster, K; Zanotti, K | 1 |
| Akiyama, Y; Hotta, K; Inoue, A; Kodama, T; Kunitoh, H; Kusaba, H; Nokihara, H; Ohe, Y; Saijo, N; Sawada, M; Sekine, I; Shimoyama, T; Tamura, T; Watanabe, H; Yamamoto, N | 1 |
| Demura, T; Harabayashi, T; Ishikawa, R; Koyanagi, T; Mitsuhashi, K; Murakumo, M; Seki, H; Shinohara, N; Suzuki, S; Toyota, H | 1 |
| Bangert, S; Bishop, WR; Fossella, FV; Glisson, BS; Herbst, RS; Hong, WK; Khuri, FR; Kies, MS; Kim, ES; Kirschmeier, P; Lu, C; Meyers, ML; Munden, RF; Papadimitrakopoulou, V; Shin, DM; Statkevich, P; Tendler, C; Thall, PF; Thompson, E; Wang, XM; Zhu, Y | 1 |
| Anagnostopoulos, A; Aravantinos, G; Bafaloukos, D; Daniilidis, J; Dimopoulos, MA; Fountzilas, G; Janinis, J; Kalofonos, HP; Kalogera-Fountzila, A; Makatsoris, T; Nikolaidis, P; Rigatos, SK; Samantas, E; Stathopoulos, GP; Tolis, C | 1 |
| Fujiwara, K; Hisamoto, A; Hosokawa, S; Hotta, K; Kiura, K; Kozuki, T; Kuyama, S; Satoh, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Antoniou, D; Bastani, S; Charalambatou, M; Dimitroulis, I; Georgatou, N; Gerogianni, A; Giamboudakis, P; Grigoratou, T; Kalatzi, E; Katis, K; Loukides, S; Marossis, K; Michalopoulou, P; Paspalli, A; Rigatos, SK; Stathopoulos, GP; Stoka, M; Tsavdaridis, D; Vergos, K; Veslemes, M | 1 |
| Bonneterre, J; Catimel, G; Tubiana-Hulin, M | 1 |
| Fujimoto, M; Furukawa, J; Higaki, J; Hoashi, T; Ikeda, N; Inui, N; Kogire, M; Matsunami, T; Nakano, K; Nishi, T; Nomura, T; Ogino, N; Takagaki, K; Takeda, C; Tanaka, H; Uenishi, M; Yamada, S; Yamanaka, E; Yamasaki, M; Yamauchi, E; Yayoi, E | 1 |
| Biamonte, R; Cartenì, G; Danese, S; De Laurentiis, M; De Matteis, A; De Placido, S; Di Vagno, G; Febbraro, A; Gallo, C; Gasparini, G; Greggi, S; Lauria, R; Lombardi, AV; Manzione, L; Marinaccio, M; Naglieri, E; Perrone, F; Pignata, S; Scambia, G; Valerio, MR | 1 |
| Kim, CH; Kim, HT; Lee, JC; Park, YH; Ryoo, BY | 1 |
| A'Hern, R; Cole, C; Everard, M; Gibbens, I; Gore, M; Hall, G; Harries, M; Jenkins, A; Kaye, S; Moss, C; Perren, T; Pizzada, O; Shah, R | 1 |
| Aldrighetti, D; Baldini, E; Bolognesi, A; Bruzzi, P; Carnino, F; Conte, PF; Costantini, M; Giannessi, P; Guarneri, V; Mammoliti, S; Moyano, A; Prochilo, T; Rosso, R; Salvadori, B; Venturini, M | 1 |
| Castellano, D; Cortés-Funes, H; Hitt, R; Jimeno, A; Millán, JM | 1 |
| Blohmer, JU; Elling, D; Heilmann, V; Köhler, G; Krocker, J; Michniewicz, K; Morack, G; Possinger, K; Schaller-Kranz, T; Schmid, P | 1 |
| Barbone, F; Belvedere, O; Ceschia, T; Fasola, G; Follador, A; Grossi, F; Guglielmi, A; Morelli, A; Puglisi, F; Recchia, L; Rizzato, S; Sibau, A; Sobrero, AF; Talmassons, G; Vigevani, E | 1 |
| Briasoulis, E; Karavasilis, V; Pavlidis, N; Pentheroudakis, G; Rammou, D; Tzamakou, E | 1 |
| Fujii, T; Hirakawa, T; Kamura, T; Katsumata, N; Mushika, M; Onda, T; Saito, T; Tsunematsu, R; Yamamoto, K; Yasugi, T; Yoshikawa, H | 1 |
| Edwards, RP; Gallion, HH; Kelley, JL; Kunschner, AJ; Sit, AS | 1 |
| Lilenbaum, RC | 1 |
| Atkinson, R; Coleman, R; Gabra, H; Gordon, A; Hay, A; Jayson, GC; Kaye, SB; Parkin, D; Paul, J; Vasey, PA | 1 |
| Azumi, T; Daito, K; Hirai, K; Hirai, T; Hojo, T; Inui, H; Shiozaki, H; Ueda, K; Watatani, M; Yamato, M | 1 |
| Guan, ZZ; Hawkins, M; Liu, DG; Luo, HY; Soon-Shiong, P; Teng, XY; Yao, ZW; Zhou, NN | 1 |
| Aravantinos, G; Christodoulou, C; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Papakostas, P; Razis, E; Skarlos, D; Tsavdaridis, D | 1 |
| Barone, C; Bertetto, O; Birocco, N; Colantonio, I; Dongiovanni, D; Numico, G; Schena, M | 1 |
| Foo, KF; Leong, SS; Lim, WT; Tan, EH; Tan, SB; Tan, T; Tay, MH; Thng, CH; Toh, CK; Wee, J | 1 |
| Choi, SJ; Kim, HT; Park, YH; Ryoo, BY; Yang, SH | 1 |
| Addeo, A; Barone, C; Berruti, A; Bertetto, O; Buffoni, L; Dongiovanni, D; Dongiovanni, V; Fissore, C; Ottaviani, D; Polimeni, MA | 1 |
| Domchek, SM; Fox, K; Hwang, WT; Schwartz, J | 1 |
| Bighin, C; Catzeddu, T; Del Mastro, L; Fratino, L; Maggi, E; Manzione, L; Marenco, D; Perrone, F; Repetto, L; Rosso, R; Venturini, M; Venturino, A; Zagonel, V | 1 |
| Flaherty, K; Konkle, BA; Kramer, A; Morgan, M; O'Dwyer, PJ; Stevenson, JP; Veronese, ML | 1 |
| Ansari, R; Einhorn, LH; Fisch, MJ; Fox, E; Juliar, B; Li, J; Sweeney, CJ; Yiannoutsos, C | 1 |
| Babb, JS; Cheng, J; Cohen, RB; Damsker, JA; Feigenberg, SJ; Horwitz, EM; Kramer, NM; Langer, CJ; Nicolaou, N; Ridge, JA; Sherman, EJ | 1 |
| Cai, RG; Chu, DT; Cui, CX; Huang, J; Meng, PJ; Sun, Y; Wang, JW; Yang, L; Zhang, MJ | 1 |
| Boezen, HM; Bos, AM; de Graaf, H; de Swart, CA; De Vos, FY; de Vries, EG; Schaapveld, M; van der Zee, AG; Willemse, PH | 1 |
| Fujii, S; Goto, E; Imamura, F; Kishi, H; Kiyofuji, C; Matsumoto, M; Mori, T; Moriyama, E; Nomura, M; Okamoto, I | 1 |
| Chang, HM; Choi, SJ; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, YH; Ryu, BY | 1 |
| Balis, F; Bates, S; Cole, D; Egorin, MJ; Flynn, BM; Fojo, T; Knutsen, T; Langham, G; Rao, VK; Ried, T; Steinberg, SM; Wangsa, D | 1 |
| He, PQ; Li, YF; Liu, GY; Shen, ZZ; Sheng, Y; Shi, JY; Su, FX; Yang, MT; Zou, Q | 1 |
| Araki, K; Hirabayashi, N; Kataoka, M; Kobayashi, M; Kojima, H; Kondo, K; Matsui, T; Miyashita, Y; Nakao, A; Nakazato, H; Sakamoto, J; Takiyama, W | 1 |
| Chi, KN; Chia, SK; Dixon, R; Gelmon, KA; Newman, MJ; Sikic, B; Wacher, VJ | 1 |
| Chew, HK; DeNardo, GL; Denardo, SJ; Goldstein, DS; Kukis, DL; Lamborn, KR; Lara, PN; Meares, CF; Natarajan, A; O'Donnell, RT; Richman, CM; Shen, S; Tuscano, JM; Wun, T; Yuan, A | 1 |
| Estepa-Alonso, MJ; Liso-Rubio, FJ; Luis-Fernández, J; Rangel-Mayoral, JF | 1 |
| Forkert, R; Fronhoffs, S; Ko, Y; Koll, C; Neuhaus, T; Stier, S; Tuohimaa, A; Vetter, H | 1 |
| Ito, S; Kodera, Y; Mochizuki, Y; Yamamura, Y | 1 |
| Busby, E; Carey, D; Forero, A; Grizzle, WE; Khazaeli, MB; LoBuglio, AF; Meredith, RF; Robert, F; Shen, S | 1 |
| Andersen, N; Brandt, D; Davies, MJ; Murren, JR; Nadkarni, R; Parisot, N; Pizzorno, G; Psyrri, D; Rose, M; Rosenfield, AT; Zelterman, D | 1 |
| Grénman, SE; Jalkanen, JT; Kuoppala, TA; Leminen, AO; Mäenpää, JU; Puistola, US; Vuolo-Merilä, PM; Yliskoski, MH | 1 |
| Antón, A; Belón, J; Carles, J; Cervantes, A; Chaib, C; Cortés-Funes, H; Escrig, V; Hitt, R; Isla, D; Lobo, F; López-Pousa, A; Martí, JL; Martínez-Trufero, J; Pallarés, C; Pastor, P; Paz-Ares, L; Rizo, A; Sánchez, MA; Valentí, V; Vega, ME | 1 |
| Bunnell, CA; Burstein, HJ; Come, SE; Doherty, J; Gelman, R; Haldoupis, M; Harris, LN; Keshaviah, A; Moy, B; Parker, LM; Partridge, AH; Ryan, PD; Schapira, L; Schumer, ST; Winer, EP; Younger, J | 1 |
| Bang, YJ; Choi, IS; Heo, DS; Im, SA; Kim, DW; Kim, JH; Kim, NK; Kim, TY; Lee, JS; Lee, KW; Na, Ii; Oh, DY; Shin, H; Song, EK; Yun, T | 1 |
| Doki, Y; Fujita, J; Fujiwara, Y; Kan, K; Miyata, H; Monden, M; Takiguchi, S; Tsukahara, K; Yasuda, T | 1 |
| Ballas, MS; Dennis, PA | 1 |
| Barbieri, F; Bearz, A; Belloni, P; Biason, R; Ceresoli, G; Chella, A; Clerici, M; Favaretto, A; Ghi, MG; Nicoletto, MO; Oniga, F; Paccagnella, A; Riccardi, A; Ridolfi, R; Tirelli, U; Tumolo, S; Veglia, F | 1 |
| Ahn, JB; Cho, BC; Choi, HJ; Kim, CB; Kim, JH; Lee, YC; Sohn, JH | 1 |
| Mehta, D; Radhakrishnan, L; Villano, JL | 1 |
| Baba, H; Emi, Y; Kakeji, Y; Maehara, Y; Oki, E; Takahashi, I; Tokunaga, E; Ushiro, S; Watanabe, M | 1 |
| Driscoll, D; Lele, S; Odunsi, K; Rezai, K; Sharma, S | 1 |
| Hashizume, T; Hayashi, M; Kozawa, S; Miyazawa, N; Nakamura, M; Ogura, T; Takahashi, H; Watanuki, Y; Yamaguchi, N | 1 |
| Ai, B; Han, XH; He, XH; Huang, DZ; Li, B; Liu, P; Qin, Y; Shi, YK; Sun, Y; Yang, S; Zhang, CG | 1 |
| Keating, GM; Robinson, DM | 1 |
| Davidson, N; Harper, P; Harries, M; Ibrahim, N | 1 |
| Kawauchi, A; Mikami, K; Miki, T; Mizutani, Y; Nakamura, T; Nakanishi, H; Nomoto, T | 1 |
| Doi, M; Fukuhara, K; Kuwabara, M; Maeda, H; Miyamoto, S; Sumiyoshi, H; Yamasaki, M | 1 |
| Habara, K; Kawamura, S; Okumura, S; Shimada, E; Sumi, Y; Tei, M; Yamagishi, D | 1 |
| Haruta, S; Kanayama, S; Kawaguchi, R; Kobayashi, H; Tanase, Y; Yamada, Y | 1 |
| Akerley, W; Kennedy, T; Mega, T; Ready, N; Safran, H; Zaner, K | 1 |
| Bauernhofer, T; Dandachi, N; Holub, R; Samonigg, H; Schippinger, W | 1 |
| Cai, YM; Chen, ZM; Han, XH; He, XH; Liu, P; Shi, YK; Yang, S | 1 |
| Behringer, D; Figg, WD; Mielke, S; Mross, K; Sissung, TM; Sparreboom, A; Steinberg, SM | 1 |
| Chatelut, E; Henningsson, A; Karlsson, MO; Kloft, C; Wallin, J | 1 |
| Delva, R; Douville, I; Longerey, B; Pienkowski, T; Tubiana, N; Vanhoefer, U | 1 |
| Anan, K; Fujiyoshi, K; Mitsuyama, S; Tamura, K; Taniguchi, H; Tateishi, T; Yamamoto, Y | 1 |
| Misawa, A; Yasuda, M | 1 |
| Botti, G; Comella, G; Comella, P; D'Aiuto, G; De Rosa, V; Di Bonito, M; Frasci, G; Iodice, G; Rubulotta, MR; Thomas, R | 1 |
| Gu, YH; Huang, PW; Lu, KH; Shu, YQ | 1 |
| Appleman, L; Bukowski, R; Cooper, W; Grover, J; Lockhart, AC; Mayer, PR; Rothenberg, ML; Shapiro, M; Wang, KK; Zhu, AX | 1 |
| Aravantinos, G; Christodoulou, Ch; Malamos, NA; Rigatos, S; Skarlos, D; Stathopoulos, GP; Stathopoulos, J | 1 |
| Burstein, HJ; Partridge, AH; Sheib, RG; Tolaney, SM; Winer, EP | 1 |
| Akiyama, F; Furukawa, K; Hatake, K; Horikoshi, N; Ito, Y; Kasumi, F; Mizunuma, N; Sakamoto, G; Sawaki, M; Tajiri, T; Takahashi, S | 1 |
| Bae, SH; Baek, JH; Cho, GJ; Chung, HY; Chung, JS; Do, YR; Hyun, MS; Jang, JS; Kim, JG; Kwon, KY; Lee, KH; Lee, WS; Park, KU; Ryoo, HM; Sohn, CH; Sohn, SK; Song, HS; Yu, W | 1 |
| Ilson, DH; Kelsen, DP; Leichman, LP; Wadleigh, RG | 1 |
| Dakhil, S; Dy, GK; Geoffroy, FJ; Jett, JR; Krewer, KD; Krook, J; Kugler, J; Kutteh, L; Mailliard, J; Maurer, M; Rowland, K; Tazelaar, H; Wender, D | 1 |
| Barstis, J; Belani, CP; Clark, R; La Rocca, RV; Mills, GM; Nattam, SR; Perry, MC; Ramalingam, S; Rinaldi, D | 1 |
| Atkins, JN; Bearden, JD; Crowley, JJ; Dakhil, SR; Dunphy, FR; Gandara, DR; Giguere, JK; Hesketh, PJ; Kelly, K; McCoy, J; Weiss, GR | 1 |
| Bitran, JD; Burnett, D; Chiappori, AA; Eiseman, I; Ellis, PM; Hamm, JT; Lenehan, P; Lovalvo, J; Olson, S; Zinner, RG | 1 |
| Yoneda, S | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Giassas, S; Kalykaki, A; Kentepozidis, N; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P; Vamvakas, L | 1 |
| Adachi, M; Ando, K; Hirose, T; Horichi, N; Ishida, H; Kusumoto, S; Ohmori, T; Ohnishi, T; Okuda, K; Shirai, T; Sugiyama, T | 1 |
| Chao, TY; Hong, RL; Hsieh, RK; Hwang, WS; Kao, WY; Lin, CH; Wang, CH | 1 |
| Saito, Y; Suzuki, Y; Tokuda, Y | 1 |
| Hanada, N; Hori, K; Kusano, S; Momi, H | 1 |
| Leelahakorn, S; Lowathanasirikul, J; Manusirivithaya, S; Tangjitgamol, S | 1 |
| Guan, JH; Huan, HY; Mao, F; Sun, Q; Zhou, YD | 1 |
| Chen, LK; Guan, ZZ; Hang, Y; Xu, GC; Yang, QY | 1 |
| Jin, ML; Li, J; Li, Y; Shen, L; Zhang, XD; Zhang, XT | 1 |
| Beijnen, JH; Boddy, AV; Briasoulis, E; Calvert, H; Chatelut, E; Dittrich, C; Féty, R; Hempel, G; Hollema, H; Huitema, AD; Izquierdo, MA; Jodrell, DI; Joerger, M; Karlsson, M; Martoni, A; Pavlidis, N; Richel, DJ; Schellens, JH; Schrijvers, AH; Sleeboom, HP; Sorio, R; Strocchi, E; Tranchand, B; Twelves, C; Van der Vijgh, WJ; Vermorken, JB; Wilkins, J | 1 |
| Beijnen, JH; Bussink, J; Huitema, AD; Punt, CJ; Timmer-Bonte, JN; Tjan-Heijnen, VC; van Die, CE; vd Heijden, HF | 1 |
| Chang, J; Cho, BC; Choi, HJ; Chung, KY; Kim, DJ; Kim, JH; Kim, SH; Kim, SK; Park, MS; Shin, SJ; Sohn, JH | 1 |
| Azzoli, CG; Brower, M; Chia, G; Fiore, J; Hawkins, MJ; Heelan, R; Kris, MG; Miller, VA; Ng, KK; Riely, GJ; Rizvi, NA | 1 |
| Marino, P | 1 |
| Cui, BX; Jiang, J; Kong, BH; Meng, LH; Su, SL; Wang, B; Wang, LJ; Yang, XS; Zhang, YZ | 1 |
| Fujitani, K; Furukawa, H; Goto, M; Imamoto, H; Imamura, H; Imano, M; Ishida, H; Kimura, Y; Narahara, H; Shimokawa, T; Takiuchi, H | 1 |
| Aikou, T; Aridome, K; Etoh, T; Hamanoue, M; Hokita, S; Ishigami, S; Iwashita, T; Komatsu, H; Maehara, Y; Maenohara, S; Miyazono, F; Morita, S; Nakajo, A; Nakano, S; Natsugoe, S; Sakamoto, J; Satoh, K; Takiuchi, H | 1 |
| Fukushima, M; Garbo, CL; Ishiguro, H; Kitano, T; Toi, M; Ueno, T; Yanagihara, K; Yasuda, H; Yoshibayashi, H | 1 |
| Fumoleau, P; Lemevel, B; Maugard-Louboutin, C; Perrocheau, G | 1 |
| Brady, MF; Clarke-Pearson, DL; Davidson, M; Hoskins, WJ; Kucera, PR; Look, KY; McGuire, WP; Partridge, EE | 1 |
| Crown, JP; Currie, V; Gilewski, TA; Hakes, TB; Heelan, R; Lebwohl, DE; Reichman, BS; Seidman, AD; Surbone, A; Yao, TJ | 1 |
| Arbuck, SG | 1 |
| Adamo, DO; Bicher, A; Christian, MC; Davis, PA; Kohn, EC; Link, CJ; Reed, E; Sarosy, GA | 1 |
| Ajani, J; Daugherty, K; Ilson, D; Kelsen, D; Pazdur, R | 1 |
| Adcock, LL; Carlson, JW; Carson, LF; Carter, JR; Chen, MD; Dunn, D; Fowler, JM; Mitchell, SK; Saltzman, AK; Twiggs, LB | 1 |
| Green, MR; Lilenbaum, RC; MacManus, DA | 1 |
| Appelbaum, FR; Bensinger, WI; Buckner, CD; Demirer, T; Lilleby, K; Rowley, S; Schiffman, K; Storb, R | 1 |
| Abrams, JS; Adams, J; Baltz, J; Canetta, R; Christian, M; Desmond-Hellmann, S; Friedman, MA; Montello, M; Onetto, N; Vena, DA | 1 |
| Beijnen, JH; Bierhorst, F; Heimans, JJ; Huizing, MT; Mandjes, IA; Pinedo, HM; Postma, TJ; ten Bokkel Huinink, WW; Vermorken, JB; Winograd, B | 1 |
| Donehower, RC; Kennedy, MJ; Rowinsky, EK | 1 |
| Holmes, FA | 1 |
| Bonjo, CA; Comis, RL; Engstrom, PF; Johnson, S; Langer, CJ; Leighton, JC; Litwin, S; McAleer, CA; O'Dwyer, PJ; Ozols, RF | 1 |
| Georgiadis, MS; Johnson, BE; Schuler, B | 1 |
| Aisner, J; Belani, CP; Engstrom, C; Hiponia, D | 1 |
| Carey, RW; Elias, AD; Grossbard, ML; Jacobs, C; Jauss, S; Kwiatkowski, DJ; Lynch, TJ; Shulman, LN; Strauss, GM; Sugarbaker, DJ | 1 |
| Beijnen, JH; Dalesio, O; Giaccone, G; Huizing, M; Koolen, M; Pinedo, HM; Postmus, PE; ten Bokkel Huinink, WW; van Zandwijk, N; Vermorken, JB | 1 |
| Brewster, L; Green, MR; Hargis, JB; Hollis, DR; Lilenbaum, RC; Miller, AA; O'Brien, SM; Ratain, MJ; Rosner, GL; Schilsky, RL | 1 |
| Dreps, A; Gatzemeier, U; Heckmayr, M; Neuhauss, R; Pawel, JV; Schlüter, I; Wagner, H | 1 |
| Klastersky, J; Sculier, JP | 1 |
| Capri, G; Caraceni, A; Fulfaro, F; Gianni, L; Laffranchi, A; Martini, C; Munzone, E; Spreafico, C; Tarenzi, E; Villani, F | 1 |
| Gelmon, KA; O'Reilly, SE | 1 |
| Gelmon, KA; Tolcher, AW | 1 |
| Chazard, M; Corette, L; Dieras, V; Garet, F; Marty, M; Mignot, L; Morvan, F; Onetto, N; Serin, D; Tubiana, N | 1 |
| Bunn, PA; Kelly, K | 2 |
| Alberts, M; Antonia, SJ; Hilstro, J; Hubbell, D; Robinson, L; Ruckdeschel, JC; Wagner, H; Williams, C | 1 |
| Bowling, MK; Ettinger, DS; Flood, WA; Rowinsky, EK; Sartorius, SE; Wagner, J | 1 |
| Choy, H; Safran, H | 1 |
| Greco, FA; Hainsworth, JD; Stroup, SL | 1 |
| Israel, V; Jeffers, S; McRae, A; Muggia, FM; Natale, R; Rogers, M; Vafai, D; Zaretsky, S | 1 |
| Crown, JP; Gilewski, TA; Hakes, TB; Heelan, R; Lebwohl, DE; Norton, L; Reichman, BS; Seidman, AD; Surbone, A; Yao, TJ | 1 |
| Bonadonna, G; Capri, G; Egorin, MJ; Giani, A; Gianni, L; Kearns, CM; Lacatelli, A; Viganó, L | 1 |
| Alexanian, R; Arbuck, S; Delasalle, K; Dimopoulos, MA; Huber, M; Luckett, R; Weber, D | 1 |
| Francis, PA; Grant, SC; Heelan, RT; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR; Venkatraman, ES; Woolley, K | 1 |
| Barakat, R; Curtin, J; Francis, P; Hakes, T; Jones, W; Lewis, JL; Markman, M; Reichman, B; Rowinsky, E; Rubin, S | 1 |
| Benner, S; Calayag, M; Fossella, FV; Glisson, B; Huber, M; Lee, JS; Lippman, S; Murphy, WK; Perez-Soler, R; Shin, DM | 1 |
| Lilley, LL; Scott, HB | 1 |
| Foa, R; Norton, L; Seidman, AD | 1 |
| Finley, RS; Rowinsky, EK | 1 |
| Burris, HA | 2 |
| Ball, H; Barrett, RJ; Blessing, JA; Hummel, SJ; Thigpen, JT | 1 |
| Alexanian, R; Dimopoulos, MA; Luckett, R | 1 |
| Ariyoshi, Y; Fukuoka, M; Furue, H; Furuse, K; Hasegawa, K; Ishitani, K; Kanamaru, R; Niitani, H; Noda, K; Taguchi, T | 1 |
| Alakl, M; Clavel, M; Franklin, H; Piccart, M; Prove, AM; Steward, W; ten Bokkel Huinink, WW; Tursz, T; Verweij, J; Wanders, J | 1 |
| Catimel, G; Clavel, M; Franklin, H; Hanauske, A; Kaye, SB; Le Bail, N; Mattijssen, V; Piccart, M; Verweij, J; Wanders, J | 1 |
| Capri, G; Gianni, L; Munzone, E; Straneo, M | 1 |
| Greco, FA; Hainsworth, JD | 1 |
| Beijnen, J; Dalesio, O; Giaccone, G; Huizing, M; Koolen, M; Postmus, P; ten Bokkel Huinink, W; van Kralingen, K; van Zandwijk, N; Vermorken, J | 1 |
| Taguchi, T | 1 |
| Hirabayashi, K; Kono, I; Noda, K; Ogita, Y; Taguchi, T; Terajima, Y; Yakushiji, M | 1 |
| Balmaceda, C; Barakat, R; Francis, P; Hakes, T; Hann, L; Phillips, M; Schneider, J | 1 |
| Chikazawa, H; Hattori, N; Hiraiwa, E; Ishikawa, K; Kadota, T; Kawano, S; Koizumi, S; Kondoh, H; Kuroyanagi, K; Sakakura, K | 1 |
| Akerley, W; Choy, H; Clark, J; Glantz, M; Leone, L; Papa, A; Puthawala, Y; Rege, V; Safran, H; Soderberg, C | 1 |
| Arbuck, SG; Chaudhry, V; Donehower, RC; Eisenhauer, EA; Rowinsky, EK | 1 |
| Forastiere, AA | 1 |
| Eisenhauer, E; Swenerton, K; ten Bokkel Huinink, WW | 1 |
| Adachi, I; Aoyama, H; Horikoshi, N; Narabayashi, M; Taguchi, T; Takashima, S; Watanabe, T | 1 |
| Trudeau, ME | 2 |
| Chang, AY; DeVore, R; Johnson, D | 1 |
| Bowling, K; Chen, TL; Donehower, RC; Kennedy, MJ; Noe, DA; Rowinsky, EK; Sartorius, S; Zahurak, ML | 1 |
| Blessing, JA; Lentz, SS; McGuire, WP; Moore, D; Photopulos, G | 1 |
| Amadori, D; Casadei Giunchi, D; Frassineti, GL; Gentile, A; Ravaioli, A; Salzano, E; Tienghi, A; Zoli, W | 1 |
| Catimel, G; Chazard, M; Dieras, V; Dumortier, A; Garet, F; Graffand, N; Guastalla, JP; Kayitalire, L; Pellae-Cosset, B; Pouillart, P; Soler-Michel, P; Spielmann, M | 1 |
| Baldini, E; Biadi, O; Conte, PF; DaPrato, M; Gentile, A; Giannessi, PG; Mariani, M; Michelotti, A; Salvadori, B; Tibaldi, C | 1 |
| Diergarten, K; duBois, A; Hecker, D; Janicke, F; Konecny, G; Kuhnle, H; Lindner, C; Lisboa, BW; Luck, HJ; Meerpohl, HG; Thomssen, C; Untch, M | 1 |
| Tolcher, AW | 1 |
| Harstrick, A; Klaassen, U; Seeber, S; Wilke, H | 1 |
| Balcerzak, SP; Benedetti, J; Natale, RB; Weiss, GR | 1 |
| Fleming, GF; Janisch, L; Ratain, MJ; Vogelzang, NJ; Vokes, EE | 1 |
| Dreps, A; Gatzemeier, U; Heckmayer, M; Neuhauss, R; Schlüter, I; von Pawel, J; Wagner, H | 1 |
| Adams, D; Belli, L; Gottfried, M; LeCesne, A; LeChevalier, T; Pellae-Cosset, B; Ruffie, P; Tete, L | 1 |
| Choy, H; Cole, BF; Yee, L | 1 |
| Green, MR; Lilenbaum, RC; Lynch, TJ; Miller, AA; Ratain, MJ; Rosner, GL; Schilsky, RL | 1 |
| Armand, JP; Couteau, C; Goncalves, E; Terret, C; Yakendji, K | 1 |
| Drinkard, LC; Golomb, HM; Hoffman, PC; Krauss, SA; Masters, GA; Samuels, BL; Vokes, EE | 1 |
| Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hui, L | 1 |
| Palackdharry, CS | 1 |
| Benson, AB; Einzig, AI; Lipsitz, S; Wiernik, PH | 1 |
| Archer, PG; Jones, RB; Merouani, A; Schrier, RW; Shpall, EJ | 1 |
| Awada, A; Bruning, P; Gamucci, T; Klijn, J; Kusenda, Z; Paridaens, R; Piccart-Gebhart, MJ; Roy, JA; Van Vreckem, A | 1 |
| Boesgaard, M; Dombernowsky, P; Gehl, J; Jensen, BV; Paaske, T | 1 |
| Amadori, D; Frassineti, GL; Gentile, A; Milandri, C; Ravaioli, A; Salzano, E; Tienghi, A; Zoli, W | 1 |
| Baldini, E; Conte, PF; Da Prato, M; Gennari, A; Gentile, A; Michelotti, A; Salvadori, B; Salzano, E; Tibaldi, C | 1 |
| Baldini, E; Conte, PF; Da Prato, M; Gennari, A; Giannessi, PG; Michelotti, A; Salvadori, B; Tibaldi, C | 1 |
| Alvarez, RD; Armstrong, DK; Barker, SD; Bookman, MA; Fleming, GF; Horowitz, IR; McGuire, WP; O'Reilly, S; Ozols, RF; Rowinsky, EK; Schilder, RJ; Walczak, JR | 1 |
| Bakker, PJ; Beijnen, JH; Bierhorst, FJ; Dalesio, O; Giaccone, G; Huizing, MT; Koolen, MG; Lai, A; Pinedo, HM; Postmus, PE; Rosing, H; ten Bokkel Huinink, WW; van der Vijgh, WJ; van Warmerdam, LJ; van Zandwijk, N; Veenhof, CH; Vermorken, JB | 1 |
| Bunn, PA | 1 |
| Hanske, M; Hecker, D; Heider, A; Koschel, G; Niederle, N; von Pawel, J; Wagner, H | 1 |
| Akerley, W | 2 |
| Athanasiadis, A; Fountzilas, G; Kosmidis, P; Mylonakis, N; Samantas, E; Skarlos, D | 1 |
| Favaretto, A; Oniga, F; Ossana, L; Paccagnella, A | 1 |
| Corgna, E; Crinó, L; Gentile, A; Masiero, P; Palladino, M; Pozzi, E; Salsano, V; Scagliotti, GV; Tonato, M | 1 |
| Eisenhauer, E; Latreille, J; Paul, K; Shepherd, FA | 1 |
| Aisner, J; Bahri, S; Belani, CP; Capazolli, MJ; Day, R; Engstrom, C; Hiponia, D; Jett, J | 1 |
| Coatsworth, S; Einzig, AI; Recio, A; Rodriquez, R; Schuchter, LM; Wiernik, PH | 1 |
| Beijnen, JH; Boonstra, H; de Vries, EG; Piersma, H; van der Graaf, WT; Veldhuis, GJ; Willemse, PH | 1 |
| Bauknecht, T; Bochtler, H; Diergarten, K; du Bois, A; Köchli, O; Kreienberg, R; Kühnle, H; Luck, HJ; Meerpohl, HG; Möbus, V | 1 |
| Beijnen, JH; Giaccone, G; Helmerhorst, TJ; Huizing, MT; Koolen, MG; Postmus, PE; ten Bokkel Huinink, WW; van der Vijgh, WJ; van Warmerdam, LJ; van Zandwijk, N; Veenhof, CH | 1 |
| Akerley, W; Altenhein, E; Bland, K; Choy, H; Cicchetti, G; Hesketh, PJ; King, TP; Lopez, F; Radie-Keane, K; Rosmarin, A; Safran, H; Sikov, W; Wanebo, HJ; Wolf, B | 1 |
| Burnett, A; Garcia, A; Greco, FA; Groshen, S; Hainsworth, JD; Jeffers, S; Liang, LJ; Miller, P; Morrow, CP; Muderspach, L; Muggia, FM; Paradiso, LJ; Roman, L; Tan, M; Uziely, B | 1 |
| Capri, G; Gianni, L | 1 |
| Bonneterre, J; Catimel, G; Dieras, V; Dumortier, A; Garet, F; Graffand, N; Guastalla, JP; Kayitalire, L; Pellae-Cosset, B; Pouillart, P; Spielmann, M; Tubiana-Hulin, M | 1 |
| Diergarten, K; du Bois, A; Hecker, D; Jänicke, F; Konecny, G; Kühnle, H; Lindner, C; Lisboa, BW; Lück, HJ; Meerpohl, HG; Thomssen, C; Untch, M | 1 |
| Panagos, GE | 1 |
| Davison, JD; Francis, PA; Ganju, V; Michael, M; Millward, MJ; Rischin, D; Shapiro, JD; Toner, GC | 1 |
| Caleffi, M; Ferreira Filho, AF; Kalakun, L; Koya, R; Mans, DR; Menke, CH; Pohlman, P; Schunemann, H; Schwartsmann, G; Venegas, LF; Xavier, N | 1 |
| Boyd, JH; Dunleavy, TL; Dunphy, CH; Dunphy, FR; Harrison, BR; Hilton, JG; Kim, HJ; McDonough, EM; Minster, JR; Rodriguez, JJ | 1 |
| Carlson, JW; Carson, LF; Copeland, LJ; Fowler, JM; Mayer, AR; Mitchell, SK | 1 |
| Beijnen, JH; Birkhofer, MJ; Helmerhorst, TJ; Huizing, MT; Lai, A; Rodenhuis, S; Rosing, H; Schaefers, MC; ten Bokkel Huinink, WW; van Warmerdam, LJ; Veenhof, CH | 1 |
| Gordon, AN; Matthews, CM; Nemunaitis, J; Stringer, CA; Willis, DL | 1 |
| Aloe, A; Atlante, G; Calabresi, F; Cognetti, F; De Marco, S; Iacovelli, A; Nardi, M | 1 |
| Adamkiewicz, BB; Ellis, GK; Gralow, JR; Livingston, RB; Long, CA; McGuirt, C; White, R; Williams, MA | 1 |
| Casaretti, R; Comella, G; Comella, P; Daponte, A; Fiore, F; Frasci, G; Gravina, A; Guida, C; Parziale, A; Scoppa, G | 1 |
| Adamson, PC; Balis, FM; Berg, SL; Blaney, SM; Krailo, MD; Mosher, R; O'Brien, M; Poplack, DG; Reaman, GH; Seibel, NL | 1 |
| Bell, DR; Bishop, JF; Friedlander, ML; Levi, JA; Michael, M; Olver, IN; Smith, JG; Toner, GC; Zalcberg, JR | 1 |
| Diéras, V | 2 |
| Valero, V | 3 |
| Delorme, F; Janowska, A; Mackey, J; Nabholtz, JM; Noel, D; Paterson, A; Riva, A; Smylie, M | 1 |
| Azli, N; Delecroix, V; Féty, R; Fumoleau, P; Perrocheau, G | 1 |
| Aylesworth, C; Bellet, R; Burris, H; Drengler, R; Peacock, N; Ravdin, P; Rodriguez, G; Rowinsky, E; Smith, L; Von Hoff, D; White, L | 1 |
| Baldini, E; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Dell'Anna, R; Gennari, A; Gentile, A; Innocenti, F; Mariani, M; Michelotti, A; Salvadori, B; Tibaldi, C | 1 |
| Cavalli, F; Cerny, T; de Jong, J; Goldhirsch, A; Martinelli, G; Pagani, O; Sessa, C; Zimatore, M | 1 |
| Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K | 2 |
| Curé, H; Diéras, V; Guastalla, JP; Jacquin, JP; Leduc, B; Mignot, L; Mousseau, M; Orfeuvre, H; Paraïso, D; Pujade-Lauraine, E; Tubiana-Mathieu, N; Viens, P; Vincent, P; Weber, B | 1 |
| Bauknecht, T; Costa, S; du Bois, A; Jackisch, C; Lück, HJ; Meier, W; Möbus, V; Nitz, U; Olbricht, S; Richter, B; Schröder, W; Warm, M | 1 |
| Alvarez, AM; Blajman, C; Breier, S; Cazap, E; Cóppola, FS; Ezcurdia, L; Fasce, H; Fein, L; Jovtis, SL; Lewi, D; Luchina, AM; Martínez, CA; Mickiewicz, E; Pasccón, G; Polera, J; Politi, PM; Rondinón, M; Rubio, G; Temperley, G; Triguboff, E; Uranga, G | 1 |
| Benito, D; Casado, A; Cervantes, A; del Campo, JM; Escobedo, A; Massuti, B; Mendiola, C; Moyano, A; Ojeda, B; Poveda, A | 1 |
| Aravantinos, G; Athanassiadis, A; Bafaloukos, D; Bamia, C; Fountzilas, G; Karphathios, S; Kosmidis, P; Papakostas, P; Pavlidis, N; Skarlos, DV; Stathopoulos, GP | 1 |
| Abu-Rustum, NR; Aghajanian, C; Barakat, RR; Fennelly, D; Shapiro, F; Spriggs, D | 1 |
| Edelman, MJ; Houston, J; Lauder, I; Meyers, FJ | 1 |
| Klaassen, U; Seeber, S | 1 |
| Gradishar, WJ | 1 |
| Chan, S | 1 |
| al-Tweigeri, T; Au, D; Delorme, F; Mackey, JR; Nabholtz, JM; Noel, D; Paterson, AH; Riva, A; Sansregret, E; Smylie, M | 1 |
| Chamberlain, MC; Kormanik, PA | 1 |
| Brain, E; Cvitkovic, E; Delord, JP; Lokiec, F; Misset, JL; Mita, A; Soulié, P; Taamma, A; Trandafir, L; Vannetzel, JM | 1 |
| Dimery, I; Garcia, AA; Jeffers, S; Muggia, FM; Parimoo, D; Rogers, M | 1 |
| Bachelot, T; Biron, P; Blay, JY; Catimel, G; Chauvin, F; Droz, JP; Guastalla, JP; Merrouche, Y; Ray-Coquard, I | 1 |
| Akerley, W; Choy, H; Glantz, M; Joseph, P; Leone, L; Rege, V; Rodrigues, B; Sambandam, S; Wingate, P; Yee, L | 1 |
| Bruno, R; Burris, HA; Chevallier, B; Fossella, FV; Fumoleau, P; Hille, D; Kaye, SB; Ravdin, PM; Rigas, JR; Riva, A; Seidman, AD; Sheiner, LB; ten Bokkel Huinnink, WW; Valero, V; van Oosterom, AT; Verweij, J; Vivier, N | 1 |
| Caponigro, F; Facchini, G; Gentile, M; Gravina, A; Iaffaioli, RV; Illiano, A; Muto, P; Tortoriello, A | 1 |
| Berkowitz, R; Bunnell, CA; Buswell, L; Muto, M; Sheets, E; Shulman, LN; Thompson, L | 1 |
| de Bruijn, EA; Groult, V; Locci-Tonelli, D; Planting, AS; Pronk, LC; Schellens, JH; Schrijvers, D; van Oosterom, AT; Verweij, J | 1 |
| Eisenhauer, EA; Vermorken, JB | 1 |
| Bergh, J; Freijs, A; Karlsson, MO; Larsson, R; Molnar, V | 1 |
| Dubbelman, R; Hiemstra, A; Lustig, V; Rodenhuis, S; ten Bokkel Huinink, WW | 1 |
| Saijo, N; Sekine, I; Yamazaki, S | 1 |
| Altmannsberger, HM; Hassenstein, EO; Rexroth, G; Rösch, W | 1 |
| Eckhardt, S | 1 |
| Antman, K; Ayello, J; Bagiella, E; Balmaceda, C; Dunleavy, J; Fung, B; Garrett, T; Heitjan, D; Hesdorffer, C; Kaufman, E; McGovern, T; Papadopoulos, K; Savage, D; Tiersten, A; Vahdat, LT | 1 |
| Barbarulo, D; Budillon, A; Capasso, I; Caponigro, F; Caratení, G; Casaretti, R; Comella, G; Comella, P; D'Aiuto, G; Daponte, A; Frasci, G; Gentile, A; Gravina, A; Maiorino, L; Thomas, R | 1 |
| Anderson, N; Bern, M; Coco, F; Dow, E; Gotthardt, S; Lokich, J; Oliynyk, P | 1 |
| Benson, LT; Einzig, AI; Kaplan, J; Tan, V; Tentoramano, L; Wadler, S; Wiernik, PH | 1 |
| Bertino, JR; Casper, ES; Ilson, D; Leung, D; Pfister, D; Schwartz, GK; Sugarman, A; Waltzman, RJ; Woodruff, J | 1 |
| Bolis, G; Bookman, MA; Fields, SZ; Gordon, A; Krebs, JB; Lissoni, A; Malmström, H | 1 |
| Booser, DJ; Burris, HA; Earhart, RH; Erban, JK; Esparza-Guerra, L; Holmes, FA; Hortobagyi, GN; Jones, SE; Mennel, RG; Rahman, Z; Ravdin, PM; Schottstaedt, MW; Valero, V; Von Hoff, DD | 1 |
| Paridaens, R; Thomas, J; Van Oosterom, A; Van Vaerenbergh, W; Wildiers, J | 1 |
| Archer, CD; Coombes, RC; English, J; Khan, S; Lowdell, C; Sinnett, HD | 1 |
| Beijnen, JH; Dubbelman, RC; Hillebrand, MJ; Koopman, FJ; Panday, VR; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van Tellingen, O | 1 |
| de Boer, M; de Wit, R; Kerger, J; Kruit, WH; Stoter, G; Verweij, J | 1 |
| Androulakis, N; Chalkiadakis, G; Georgoulias, V; Kakolyris, S; Kourousis, C; Maltezakis, G; Metaxaris, G; Samonis, G; Souglakos, J; Vlachonikolis, J | 1 |
| Bonner, HS; Haller, DG; Huang, K; Recio, A; Shaw, LM; Vaughn, DJ | 1 |
| Armand, JP; Couteau, C | 1 |
| Baba, S; Ebihara, S; Horiuchi, M; Ichikawa, G; Inuyama, Y; Kamata, S; Kanzaki, J; Kataura, A; Kida, A; Konno, A; Kono, N; Kubota, A; Matsunaga, T; Matsuura, H; Miyake, H; Moriyama, H; Saijo, S; Saito, H; Sakai, M; Sasaki, Y; Satake, B; Taguchi, T; Takeoda, S; Togawa, K; Tsukuda, M | 1 |
| Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Schiza, S | 1 |
| Anderson, N; Bern, M; Coco, F; Dow, E; Lokich, JJ | 1 |
| Belli, L; Bérille, J; Bougon, N; Douillard, JY; Ibrahim, N; Le Chevalier, T; Monnier, A; Ruffie, P; Sun, XS | 1 |
| Beijnen, JH; Beusenberg, FD; Doyle, E; Hearn, S; Herben, VM; Panday, VR; Richel, DJ; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van der Vange, N | 1 |
| Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Katsogridakis, K; Kotsakis, T; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Vlachonikolis, J | 1 |
| Egorin, MJ; Fry, D; Gradishar, WJ; Liebes, L; Mendoza, S; Sparano, JA; Speyer, J; Sridhara, R | 1 |
| Balis, FM; Blaney, SM; Hutchinson, R; Krailo, M; Mosher, RB; O'Brien, M; Reaman, GH; Seibel, NL | 1 |
| Ellis, GK; Gralow, JR; Livingston, RB; Pierce, HI; Williams, MA | 1 |
| Aapro, M; Alakl, M; Bezwoda, WR; Deschênes, L; Douma, J; Drbal, J; Genot, JY; Hupperets, PS; Melnychuk, D; Molino, A; Murawsky, M; Nabholtz, JM; Nagykalnai, T; Nortier, JW; Pannuti, F; Rapoport, B; Richel, DJ; Rosso, R; Senn, HJ; Siedlecki, P; Skarlos, D; Tomiak, EM; Trillet-Lenoir, V; Vandenberg, TA; Wilking, N | 1 |
| Candalh, E; Kramar, A; Lebecq, A | 1 |
| Bertucci, D; Goh, BC; Mani, S; Ratain, MJ; Vogelzang, NJ; Vokes, EE | 1 |
| Corgna, E; Crinó, L; Gentile, A; Marracolo, F; Novello, S; Palladino, M; Pozzi, E; Salsano, G; Scagliotti, GV; Selvaggi, G; Tonato, M | 1 |
| Alvarez, A; Balbiani, L; Bertoncín, AM; Breier, S; Cazap, E; Cóppola, F; Di Notto, MR; Estévez, R; Grasso, S; Jovtis, S; Lewi, D; Mickiewicz, E; Pascual, M; Pazos, C; Róndinón, M; Suárez, A; Témperley, G; Trigo, M; Triguboff, E; Uranga, G; Ventriglia, M | 1 |
| Gerstner, JB; Grill, JP; Jett, JR; Kirschling, RJ; Krewer, KD; Kugler, JW; Kuross, SA; Marks, RS; Michalak, JC; Windschitl, HE | 1 |
| Ames, F; Asmar, L; Booser, DJ; Buzdar, AU; Frye, D; Hortobagyi, GN; Hunt, K; Ibrahim, N; Kau, SW; Manuel, N; McNeese, M; Singletary, SE; Smith, TL; Strom, E; Theriault, RL; Valero, V | 1 |
| Fattorossi, A; Greggi, S; Leone, G; Mancuso, S; Menichella, G; Panici, PB; Perillo, A; Pierelli, L; Salerno, G; Scambia, G | 1 |
| Burger, HU; Burris, HA; Drengler, RL; Eckhardt, SG; Griffin, T; Kraynak, M; Moczygemba, J; Reigner, B; Rodrigues, G; Rowinsky, EK; Villalona-Calero, MA; Von Hoff, DD; Weiss, GR | 1 |
| Fossella, FV; Fox, NJ; Glisson, BS; Hong, WK; Kurie, JM; Lee, JS; Murphy, WK; Nyberg, DA; Perez-Soler, R; Pisters, KM; Ross, MB; Shin, DM | 1 |
| Belli, M; Bilancia, D; Carpagnano, F; Cioffi, R; Comella, G; Comella, P; Contu, A; De Cataldis, G; De Lena, M; Frasci, G; Lorusso, V; Maiorino, L; Manzione, L; Mascia, V; Massidda, B; Micillo, E; Natale, M; Nicolella, GP; Panza, N; Pusceddu, G | 1 |
| Ackland, S; Bishop, JF; Canetta, R; Dewar, J; Goldstein, D; Gurney, H; Kennedy, I; Levi, J; Olver, IN; Smith, J; Stephenson, J; Tattersall, MH; Toner, GC; Walpole, E | 1 |
| Blessing, JA; Gershenson, DM; McGehee, R; Rose, PG | 1 |
| Dombernowsky, P; Hansen, HH; Stenbygaard, LE; Sørensen, JB | 1 |
| Bunn, PA; Kelly, K; Murphy, J; Pan, Z; Wood, ME | 1 |
| Boston, J; Gordon, AN; Hancock, KC; Matthews, CM; Nemunaitis, J; Stringer, CA | 1 |
| Baccala, P; Berg, D; Clark, JW; Finkelstein, D; Fuchs, CS; Grenon, N; Grossbard, ML; Lynch, TJ; Mayer, RJ; Ryan, DP; Seiden, MV | 1 |
| Le Cesne, A; Llombart, A; Rixe, O; Spielmann, M; Sverdlin, R; Zelek, L | 1 |
| Lyerly, HK; Morse, MA; Vredenburgh, JJ | 1 |
| Antonopoulos, MJ; Katsikas, M; Kosmas, C; Malamos, NA; Polyzos, A; Tsavaris, NB | 1 |
| Alexandre, J; Bensmaïne, A; Bleuzen, P; Bonneterre, J; Chahine, A; Cvitkovic, E; Faivre, S; Guastalla, J; Mahjoubi, M; Marty, M; Misset, JL; Spielman, M; Sutherland, W; Viens, P | 1 |
| Bartholomeus, S; Bleiberg, H; Brassinne, C; Cazenave, I; de Valeriola, D; Hennebert, P; Kerger, J; Kusenda, Z; Lefresne-Soulas, F; Piccart, M; Selleslags, J; Van Den Neste, E; Wythouck, H | 1 |
| Beijnen, JH; Bult, A; Huizing, MT; Lustig, V; Rodenhuis, S; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van Warmerdam, LJ | 1 |
| Ayala, F; de Arriba, F; Gómez-Espuch, J; Lozano, ML; Moraleda, JM; Ortuño, F; Vallejo, C; Vicente, V | 1 |
| Goto, K; Hojo, F; Hosomi, Y; Kakinuma, R; Kodama, K; Matsumoto, T; Mito, K; Moriyama, E; Niho, S; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Tanaka, K; Uramoto, H | 1 |
| Hatae, M; Kouno, S; Maeda, Y; Nakamura, T; Onishi, Y; Yamamoto, F | 1 |
| Cacciari, N; Martoni, A; Zamagni, C | 1 |
| de Matteis, A; Landi, G; Nuzzo, F; Perrone, F; Rossi, E | 1 |
| Bessa, EH; Lena, H; Paillotin, D; Pérol, M; Robinet, G; Schuller-Lebeau, MP; Taytard, A; Thomas, P; Vergnenègre, A | 1 |
| Aviles, V; Chalian, AA; Kligerman, MM; Machtay, M; Mirza, N; Rosenthal, DI; Treat, J; Weber, RS; Weinstein, GS | 1 |
| Boukis, H; Janinis, J; Lefantzis, D; Panagos, G; Papadakou, M; Poulis, A; Xidakis, E | 1 |
| Carpino, A; Cognetti, F; D'Ottavio, AM; Ferraresi, V; Giannarelli, D; Marsella, A; Milella, M; Nisticò, C; Papaldo, P; Terzoli, E; Thorel, MF; Vaccaro, A | 1 |
| Bol, CJ; Palmer, PA; Sparreboom, A; van Beurden, V; van der Burg, ME; van der Gaast, A; van Zuylen, L; Verweij, J; Woestenborghs, R | 1 |
| Berkowitz, R; Cannistra, SA; Kim, Y; Matulonis, U; Niloff, J; Quartulli, M; Seiden, M; Tung, N | 1 |
| Andersen, JE; Atkinson, RJ; Bacon, M; Baron, B; Bertelsen, K; Birt, A; Blom, R; Cassidy, J; Grimshaw, R; James, K; Kaern, J; Kaye, S; Lhoas, F; Lindvall, B; Mangioni, C; Nardi, M; Paul, J; Pecorelli, S; Piccart, MJ; Roy, JA; Simonsen, E; Stuart, G; Swenerton, KD; Timmers, P; Trope, C; Tumolo, S; Vergote, I; Zee, B | 1 |
| Kris, MG; Miller, VA | 1 |
| Bilgrami, S; Bona, RD; Edwards, RL; Feingold, JM; Kapur, D; Khan, AM; Rodriguez-Pinero, F; Tutschka, PJ | 1 |
| Bennouna, J; Berille, J; Douillard, JY; Lemarie, E; Milleron, B; Monnier, A; Rivière, A; Soussan-Lazard, K; Trillet-Lenoir, V | 1 |
| Androulakis, N; Dimopoulos, MA; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, T; Kouroussis, C; Samonis, G; Souglakos, J; Voloudaki, A | 1 |
| Chan, CC; Chua, ET; Goh, BC; Kong, HL; Lee, SC; Lehnert, M; Lim, HL; Ng, AW; Wee, J; Wong, JE | 1 |
| Bella, MA; Beretta, MD; Cocconi, G; Ferrozzi, F; Mambrini, A; Quarta, M; Vasini, G | 1 |
| Gordon, RJ; Osterwalder, B; Planting, AS; Pronk, LC; Reigner, B; Sparreboom, A; Twelves, C; Vasey, P; Verweij, J | 1 |
| Hukom, R; Jayusman, AM; Jusuf, A; Mariono, SA; Reksodiputro, AH; Soetandyo, N; Suratman, E; Tambunan, KL | 1 |
| Halme, M; Jekunen, A; Kivisaari, L; Knuuttila, A; Linnainmaa, K; Mali, P; Mattson, K; Ollikainen, T | 1 |
| Bdolah-Abram, T; Burtness, BA; D'Andrea, E; Gollerkeri, A; Lee, FA; Psyrri, A; Rose, M | 1 |
| Guan, Z; Lin, T; Wu, H | 1 |
| Fowler, JM; Greer, BE; Horowitz, IR; McGuire, WP; Rodriguez, M; Rose, PG; Waggoner, S | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N; Nakagawa, K; Negoro, S; Niitani, H; Saka, H; Sugiura, T; Takada, M | 1 |
| Boyer, M; Gurney, H; Lewis, C; McKendrick, J; Millward, M; Richardson, G; Rischin, D; Smith, J; Toner, G | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Sarmonis, G; Sarra, E; Souglakos, J; Vardakis, N | 1 |
| Bhupalam, L; Fleming, DR; Glisson, SD; Goldsmith, GH; LaRocca, RV; Michelson, GD | 1 |
| Kosmidis, P | 1 |
| Hansen, HS; Larsen, SK; Specht, L | 1 |
| Bunn, PA; Kelly, K; Mikhaeel-Kamel, N; Murphy, J; Pan, Z; Prindiville, S | 1 |
| Apostolaki, S; Georgoulias, V; Kotsakis, A; Koukourakis, M; Mavromanomakis, E; Peraki, M; Sarra, E; Souglakos, J; Vlachonikolis, J | 1 |
| Barbarisi, A; Benassai, G; Carbone, I; Ciccarelli, PD; Crovella, F; De Rosa, P; Frattolillo, A; Iaffaioli, RV; Libutti, M; Santangelo, M; Tortoriello, A; Turitto, G | 1 |
| Carmichael, J; Howells, A; Jones, A; Lind, M; Poole, C; Stuart, N; White, J | 1 |
| Breau, JL; Brunet, A; Coulon, MA; L'Her, P; Morère, JF; Piperno-Neumann, S; Quinaux, E; Vaylet, F | 1 |
| Bauer, J; Borner, M; Crivellari, D; D'Incalci, M; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Martinelli, G; Nolè, F; Pagani, O; Sessa, C; Thürlimann, B; Zucchetti, M | 1 |
| Fujii, H; Igarashi, T; Itoh, K; Kashimura, M; Minami, H; Ohashi, Y; Ohtsu, T; Onozawa, Y; Sasaki, Y; Wakita, H; Watanabe, Y | 1 |
| Egorin, MJ; Fracasso, PM; Kerr, I; Litchman, M; Michael, M; Moore, MJ; Oza, AM; Patnaik, A; Rivkin, S; Siu, LL; Warner, E | 1 |
| Boisdron-Celle, M; Gamelin, E | 1 |
| Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M | 1 |
| Dubuc-Lissoir, J; Eisenhauer, E; Fisher, B; Grimshaw, R; Hoskins, P; Oza, A; Plante, M; Stuart, G; Vergote, I; Vermorken, J | 1 |
| Azinovic, I; Brugarolas, A; Calvo, E; Cortes, J; de Irala, J; Fernandez-Hildago, O; Garzon, C; Martinez-Aguillo, M; Martinez-Monge, R; Ramon Y Cajal, T; Rodriguez, J | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kourousis, CH; Malliotakis, P; Mavroudis, D; Sarra, E; Souglakos, J | 1 |
| Barbarisi, A; De Marino, V; Elia, S; Facchini, G; Fraioli, G; Frattolillo, A; Gentile, M; Gravina, A; Griffo, S; Iaffaioli, RV; Illiano, A; Libutti, M; Muto, P; Tortoriello, A; Turitto, G | 1 |
| Agelaki, S; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Reppa, D; Samonis, G; Souglakos, J; Vardakis, N | 1 |
| Barbieri, F; Bearz, A; Ceresoli, GL; Favaretto, A; Frustaci, S; Ghiotto, C; Oniga, F; Paccagnella, A; Schiavon, S; Villa, E | 1 |
| Amodio, A; Belli, F; Botti, C; Conti, F; Di Lauro, L; Ferraironi, A; Foggi, P; Gionfra, T; Lopez, M; Morelli, MF; Vici, P | 1 |
| Elfring, GL; Hanover, CK; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Pirotta, N; Sandler, AB; Socinski, MA | 1 |
| Adams, GL; DeConti, RC; Forastiere, AA; Leong, T; Murphy, BA; Rowinsky, E; Vlock, DR | 1 |
| Adams, AL; Boente, M; Bookman, MA; Ciccotto, S; Gallo, JM; Millenson, MM; Ozols, RF; Padavic-Shallers, K; Rogatko, A; Rogers, B; Rosenblum, N; Schilder, RJ; Weiner, LM | 1 |
| Hirabayashi, K; Hoshiai, H; Katsumata, N; Kohno, I; Noda, K; Ogita, S; Taguchi, T; Tanaka, K; Terashima, Y; Tsunematsu, R; Yakushiji, M | 1 |
| Baldelli, AM; Barni, S; Casaretti, R; Cascinu, S; Catalano, G; Catalano, V; Comella, G; Frontini, L; Graziano, F; Labianca, R | 1 |
| Balmaceda, CM; Egorin, MJ; Hesdorffer, CS; Huang, M; Kaufman, E; Papadopoulos, KP; Troxel, AB; Vahdat, LT | 1 |
| Alvarez, RD; Blessing, JA; Curtin, JP; Fowler, WC; Malfetano, JH; Mayer, AR; Rose, PG; Webster, KD | 1 |
| Balmes, P; Blanchon, F; Castelnau, O; Delaval, P; Gouva, S; Kleisbauer, JP; Léna, H; Muir, JF; Paillotin, D; Penot-Ragon, C; Perdu, D; Poirier, R; Pommier De Santi, P; Robinet, G; Thomas, P | 1 |
| Fleming, GF; Langhauser, C; Rotmensch, J; Waggoner, SE | 1 |
| Carrasco, E; Dueñas, R; Fernández, M; González, E; Jaén, A; Lozano, A; Martos, M; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Burger, RA; Carson, LF; Gallion, H; Lentz, SS; Markman, M; Spriggs, D | 1 |
| Akerman, P; Chen, MH; Gaissert, H; Graziano, S; Hesketh, PJ; Koness, J; Moore, T; Safran, H; Wanebo, HJ | 1 |
| Ansell, SM; Burch, PA; Kvols, LK; Mahoney, MR; Pitot, HC; Rubin, J | 1 |
| Bertuzzi, A; Capri, G; Cresta, S; Giani, A; Gianni, L; Grasselli, G; Locatelli, A; Materazzo, C; Perotti, A; Spreafico, C; Tarenzi, E; Valagussa, P; Viganò, L | 1 |
| Abela, K; Aravantinos, G; Bafaloukos, D; Briassoulis, E; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, E; Kalofonos, HP; Kosmidis, P; Moulopoulos, LA; Papadimitriou, C; Papakostas, P; Pavlidis, N; Razis, E; Skarlos, D | 1 |
| Agelaki, S; Androulakis, N; Bania, E; Chainis, K; Georgoulias, V; Kakolyris, S; Kalofonos, C; Kouroussis, C; Papadakis, E; Rapti, A; Sarra, E; Toubis, M; Tsiafaki, X; Vardakis, N | 1 |
| Aoki, D; Kikuchi, Y; Kimura, E; Kita, T; Nishida, M; Nozawa, S; Ochiai, K; Tada, S; Tsunoda, H; Udagawa, Y; Yasuda, M | 1 |
| Brunetti, C; Carreca, I; Comella, G; Comella, P; DeCataldis, G; Frasci, G; Muci, D; Natale, M; Nicolella, G; Palmeri, S; Panza, N; Piantedosi, F; Russo, A | 1 |
| Assouline, D; Bennouna, J; Douillard, JY; Grau, B; Haller, AM; Lerouge, D; Monnier, A; Rivière, A; Sun, XS | 1 |
| Campbell, M; Cantrell, J; Cartmell, A; Ghalie, R; Harvey, J; Modiano, M; Newcomb, T; Rubin, A; Schuster, M; Urba, W | 1 |
| Fleming, GF; Grinblatt, DL; Laport, GG; Waggoner, S; Williams, SF; Zimmerman, TM | 1 |
| Athanasiadis, A; Constantinidis, TC; Delis, D; Fachantidou, E; Goutsikas, J; Hatziapostolou, P; Kontakiotis, T; Patakas, D; Zarogoulidis, K | 1 |
| Aoki, Y; Kazama, JJ; Kurata, H; Tanaka, K; Tomita, M | 1 |
| Agelidou, M; Bania, E; Georgoulias, V; Jordanoglou, J; Kakolyris, S; Kouroussis, C; Mavroudis, D; Papadakis, E; Stavrakakis, J; Tsiafaki, X; Veslemes, M; Vlachonicolis, J | 1 |
| Hopkins, U; Malik, U; Rajdev, L; Sarta, C; Sparano, JA; Wolff, AC | 1 |
| Minato, K; Mori, M; Saitoh, R; Sato, K; Takei, Y; Tsuchiya, S; Watanabe, S | 1 |
| Haga, S; Hirano, A; Imamura, H; Kajiwara, T; Kimura, K; Kinoshita, J; Nagumo, H; Okabe, T; Shimizu, T; Utada, Y; Watanabe, O | 1 |
| Agelaki, S; Androulakis, N; Christodoulakis, M; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Samonis, G; Sarra, E; Souglakos, J | 1 |
| Pawlicki, M; Rolski, J; Rysz, B; Utych, G; Wiczyńska, B; Zemełka, T | 1 |
| Gupta, YK; Katiyar, CK; Rai, K; Sharma, SS | 1 |
| Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J | 1 |
| Bunn, PA; Crowley, JJ; Gandara, DR; Kelly, K; Livingston, RB; Lovato, L; Roychowdhury, D; Taylor, SA; Zangmeister, J | 1 |
| Hada, M; Koshizuka, K; Mouri, N; Muto, S; Nakagomi, H; Serizawa, M; Tada, Y; Takano, K | 1 |
| Azinovic, I; Brugarolas, A; Fernández-Hidalgo, O; García-Rayo, S; Martín-Algarra, S; Martínez-Aguillo, M; Martínez-Monge, R; Pérez-Calvo, J; Rebollo, J; Subirá, L | 1 |
| Baker, AF; Dorr, RT | 1 |
| Kim, KM; Larson, M; Leu, KM; Schiller, JH | 1 |
| Fujimoto, K; Hirai, K; Koizumi, T; Koyama, S; Kubo, K; Nomura, H; Okada, K; Tsunoda, T | 1 |
| Aloe, A; Carlini, P; Cognetti, F; De Marco, S; Fabi, A; Magnani, E; Nardi, M; Pacetti, U; Ruggeri, EM | 1 |
| Acquino-Parsons, C; Hoskins, PJ; Lee, N; Lim, P; Pike, JA; Swenerton, KD; Wong, F | 1 |
| Gianni, L; Henningsson, A; Karlsson, MO; Sparreboom, A; Verweij, J; Viganò, L | 1 |
| Balbi, C; Balbi, GC; Calabria, G; Cardone, A; Cassese, E; Di Prisco, L; Menditto, A; Musone, R | 1 |
| Antonuzzo, A; Crinó, L; Darwish, S; Galli, L; Marrocolo, F; Novello, S; Pozzi, E; Ricci, S; Scagliotti, GV; Selvaggi, G; Sorbolini, S; Tonato, M | 1 |
| Beuzeboc, P; Diéras, V; Laurence, V; Pierga, JY; Pouillart, P | 1 |
| Akiyama, Y; Inoue, A; Kodama, T; Kunitoh, H; Kusaba, H; Ohe, Y; Saijo, N; Sawada, M; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Carman, L; Colborn, D; Gutterman, L; Jones, J; Kuebler, JP; Larrimer, N; Laufman, LR; Moore, T; Patel, T; Pritchard, J; Roach, R; Segal, M; Spiridonidis, CH; Zangmeister, J | 1 |
| Irwin, DH; Kirshner, JJ; Patel, R; Perez, EA; Vogel, CL | 1 |
| Fujimura, M; Hidaka, T; Saito, S; Sakai, M | 1 |
| Bidoli, P; Cantù, G; Cerrotta, AM; Damascelli, B; Di Tolla, G; Dosio, F; Frigerio, LF; Garbagnati, F; Lanocita, R; Leo, E; Marchianò, A; Mattavelli, F; Patelli, G; Spreafico, C; Tamplenizza, P; Tichà, V; Vespro, V; Zunino, F | 1 |
| Bastian, R; Choudhury, A; Clark, JI; Collins, S; Emami, B; Hofmeister, C; Matz, G; Melian, E; Petruzzelli, G | 1 |
| Baker, M; Billings, FT; Bradof, JE; Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Fetterly, GJ; Straubinger, RM; Tamburlin, JM | 1 |
| Chacón, JI; de Castro, J; Dorta, J; Espinosa, E; Feliu, J; González Barón, M; Lizón, J; Martin, G; Rodríguez, A; Sánchez Heras, B; Torrego, JC | 1 |
| Bischoff, J; Forstpointner, R; Geuenich, S; Gutschow, K; Heinemann, V; Hiddemann, W; Kentenich, CH; Malekmohammadi, M; Sommer, H; Stemmler, HJ | 1 |
| Barbaro, P; Console, G; Iacopino, P; Irrera, G; Martino, M; Messina, G; Morabito, F; Oliva, E; Palazzo, S; Pucci, G | 1 |
| Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D | 1 |
| Behringer, D; Gelderblom, H; Mielke, S; Mross, K; Sparreboom, A; ten Tije, AJ; van Zomeren, DM; Verweij, J | 1 |
| Doi, S; Fukuda, M; Kanda, T; Kawabata, S; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Narasaki, F; Oka, M; Soda, H; Suenaga, M; Takatani, H; Tsurutani, J | 1 |
| Nishiwaki, Y; Saijo, N; Sakai, H; Tamura, T; Watanabe, K; Yokoyama, A; Yoneda, S | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Ohe, Y; Ohmatsu, H | 1 |
| Glaspy, J; Hill, LR; Holmes, FA; Jones, SE; Liang, BC; Meza, L; Moore, M; Neumann, TA; O'Shaughnessy, JA; Savin, M; Shogan, J; Vukelja, S; Wiznitzer, I | 1 |
| Crespo, C; García-López, JL; Garrido, P; González-Martín, A; Lastra, E; Moyano, A; Pedraza, M | 1 |
| Bonazzi, C; Buda, A; Cantù, MG; Colombo, N; Dell'Anna, T; Floriani, I; Parma, G; Rossi, R; Torri, V | 1 |
| Eskens, FA; Polee, MB; Siersema, PD; Splinter, TA; Stoter, G; Tilanus, HW; van der Burg, ME; van der Gaast, A; Verweij, J | 1 |
| Bougnoux, Ph; Eymard, JC; Lotz, V; Mansouri, H; Namer, M; Spielmann, M; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Forastiere, AA; Frenette, G; Glisson, BS; Khuri, FR; Murphy, BA | 1 |
| Dueñas, MR; Fernández, M; González, E; Jaén, A; Lozano, A; Martos, M; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Botti, G; D'Aiuto, G; De Maio, E; de Matteis, A; Labonia, V; Landi, G; Mastro, AA; Nuzzo, F; Perrone, F; Rossi, E | 1 |
| Atagi, S; Haryu, H; Hosoe, S; Inoue, K; Kawaguchi, T; Kawahara, M; Mitsuoka, S; Naka, N; Ogawara, M; Okishio, K; Origasa, H; Sunami, T; Yoneda, T | 1 |
| Ames, F; Berry, D; Booser, DJ; Buzdar, AU; Frye, DK; Holmes, FA; Hortobagyi, GN; Hoy, E; Hunt, K; Ibrahim, NK; Kau, SW; Manuel, N; McNeese, MD; Rahman, Z; Rivera, E; Singletary, SE; Smith, TL; Strom, E; Theriault, RL; Thomas, E; Valero, V; Walters, R | 1 |
| Lavelle, F | 1 |
| Briasoulis, E; Haidou, C; Karavasilis, V; Pavlidis, N; Piperidou, C; Tzamakou, E | 1 |
| Angiolini, C; Baldini, A; Bergaglio, M; Canavese, G; Del Mastro, L; Garrone, O; Lambiase, A; Merlano, M; Rosso, R; Tolino, G; Venturini, M | 1 |
| Aghajanian, C; Barakat, R; Geller, G; Hensley, ML; Lovegren, M; Maki, R; Sabbatini, P; Spriggs, DR; Tong, W; Venkatraman, E | 1 |
| Alexopoulou, A; Deutsch, M; Dourakis, SP; Sevastianos, VA; Stavrianeas, N | 1 |
| Clark, B; Ettinger, DS; Forastiere, AA; Gilbert, MR; Grochow, LB; Lubejko, BG; McGuire, WP; Noe, DA; Rowinsky, EK; Sartorius, SE | 1 |
| Donehower, RC; Rowinsky, EK | 1 |
| Benjamin, RS; Legha, SS; Papadopoulos, N; Raber, M; Ring, S | 1 |
| Dutcher, JP; Einzig, A; Lipton, RB; Schwartz, EL; Strauman, JJ; Wiernik, PH | 1 |
39 review(s) available for paclitaxel and Neutropenia
| Article | Year |
|---|---|
Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis.
Topics: Adult; Albumin-Bound Paclitaxel; Breast Neoplasms; Female; Humans; Nanoparticles; Neutropenia; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2022 |
Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
Topics: Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Breast Neoplasms; Female; Humans; Myalgia; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Platinum; Prognosis; Triple Negative Breast Neoplasms | 2023 |
Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Nervous System; Neutropenia; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2019 |
Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Female; Humans; Liver Diseases; Logistic Models; Male; Middle Aged; Models, Biological; Neoplasms; Neutropenia; Nonlinear Dynamics; Paclitaxel; Young Adult | 2014 |
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Docetaxel; Enzyme Induction; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Nicotine; Paclitaxel; Polycyclic Aromatic Hydrocarbons; Quinazolines; Smoking; Taxoids | 2014 |
The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Neutropenia; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2015 |
Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Approval; Humans; Hypertension; Immunotherapy; Neovascularization, Pathologic; Neutropenia; Paclitaxel; Ramucirumab; Randomized Controlled Trials as Topic; Stomach Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Fatigue; Female; Humans; Leukopenia; Nanoparticles; Nausea; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Treatment Outcome | 2017 |
Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Humans; Liposomes; Nanoparticles; Neutropenia; Paclitaxel; Polyethylene Glycols; Tocopherols | 2012 |
[Prevention and treatment for adverse events induced by chemotherapy].
Topics: Anaphylaxis; Antineoplastic Agents; Brain Diseases; Cisplatin; Docetaxel; Fluorouracil; Humans; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Vomiting, Anticipatory | 2002 |
Challenging the platinum combinations in the chemotherapy of NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2002 |
Managing taxane toxicities.
Topics: Antineoplastic Agents, Phytogenic; Arthralgia; Bridged-Ring Compounds; Docetaxel; Drug Hypersensitivity; Humans; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Thrombocytopenia | 2003 |
A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel | 2004 |
Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Endpoint Determination; Humans; Leukopenia; Lung Neoplasms; Neoplasm Staging; Neutropenia; Paclitaxel; Prospective Studies; Survival Rate | 2005 |
[Role of G-CSF for breast cancer chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Neutropenia; Paclitaxel | 2007 |
[Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Drug Hypersensitivity; Drug Tolerance; Female; Humans; Male; Neoplasms; Neutropenia; Organoplatinum Compounds; Paclitaxel; Taxoids | 1995 |
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arrhythmias, Cardiac; Cell Cycle; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Hypersensitivity; Drug Screening Assays, Antitumor; Gastrointestinal Diseases; Humans; Mice; Microtubules; Neoplasms; Neoplasms, Experimental; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Polyethylene Glycols; Taxoids; Tubulin | 1994 |
Patient care issues: the management of paclitaxel-related toxicities.
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Hypersensitivity; Gastrointestinal Diseases; Humans; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases | 1994 |
Pharmaceutical issues of paclitaxel. Preclinical pharmacology and phase I clinical trials.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Drug Hypersensitivity; Drug Screening Assays, Antitumor; Humans; Neoplasms; Neutropenia; Paclitaxel | 1994 |
Clinical toxicities encountered with paclitaxel (Taxol).
Topics: Alopecia; Arrhythmias, Cardiac; Brain Diseases; Clinical Trials as Topic; Drug Administration Schedule; Drug Hypersensitivity; Gastrointestinal Diseases; Humans; Immunoglobulin E; Models, Biological; Muscular Diseases; Neoplasms; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Risk Factors | 1993 |
Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Female; Forecasting; Head and Neck Neoplasms; Humans; Male; Neutropenia; Paclitaxel; Thrombocytopenia | 1993 |
Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Remission Induction | 1996 |
Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.
Topics: Ambulatory Care; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Hypersensitivity; Esophagitis; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Neutropenia; Paclitaxel; Premedication; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, High-Energy; Remission Induction | 1995 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
Docetaxel: a review of its pharmacology and clinical activity.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Eruptions; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Microtubules; Neutropenia; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Taxoids; Tubulin | 1996 |
The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 1996 |
Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids | 1997 |
Review of docetaxel/doxorubicin combination in metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1997 |
Docetaxel in combination with fluorouracil for advanced solid tumors.
Topics: Adult; Aged; Animals; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Mice; Middle Aged; Mucous Membrane; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 1997 |
The taxoids. Comparative clinical pharmacology and therapeutic potential.
Topics: Alopecia; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids | 1998 |
[Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Hypersensitivity; Female; Humans; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1998 |
[The effect of docetaxel on malignant tumors].
Topics: Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Experience of treatment of lung cancer patients using paclitaxel and carboplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia | 2000 |
[Pharmacology of platinum analogs-taxanes interactions].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Drug Interactions; Humans; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
Drug interactions with the taxanes: clinical implications.
Topics: Anticonvulsants; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Interactions; Humans; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia | 2001 |
Interaction between Herceptin and taxanes.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Heart Diseases; Humans; Mice; Mice, Nude; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Nervous System Diseases; Neutropenia; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptor, ErbB-3; Salvage Therapy; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays | 2001 |
[New taxanes and epothilone derivatives in clinical trials].
Topics: Animals; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Clinical Trials, Phase I as Topic; Drug Screening Assays, Antitumor; Humans; Mice; Neutropenia; Paclitaxel; Taxoids | 2002 |
498 trial(s) available for paclitaxel and Neutropenia
| Article | Year |
|---|---|
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Analysis of Variance; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; China; Confidence Intervals; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Premenopause; Progression-Free Survival; Prospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms; Viscera | 2021 |
Paclitaxel exposure-toxicity analysis reveals a pharmacokinetic determinant for dose-limiting neutropenia in East-Asian solid tumor patients: results from two prospective, phase II studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Nasopharyngeal Neoplasms; Neutropenia; Paclitaxel; Prospective Studies | 2022 |
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04).
Topics: Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2023 |
Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Nanoparticles; Neutropenia; Paclitaxel | 2023 |
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capsules; Carboplatin; Fatigue; Female; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Phthalazines; Piperazines; Tablets; Thrombocytopenia | 2020 |
Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Chemoradiotherapy; Dose Fractionation, Radiation; Esophageal Fistula; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagitis; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Radiation Pneumonitis; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Re-Irradiation; Tumor Burden | 2020 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study.
Topics: Adenocarcinoma; Aged; Albumins; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Progression-Free Survival; Radiation-Sensitizing Agents; Thrombocytopenia; Treatment Outcome | 2020 |
Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony-Stimulating Factor Response Using Model-Based In Vitro to Clinical Translation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Cells, Cultured; Deoxycytidine; Doxorubicin; Filgrastim; Gemcitabine; Humans; Incidence; Models, Biological; Myelopoiesis; Neoplasms; Neutropenia; Paclitaxel; Polyethylene Glycols; Primary Cell Culture; Risk Assessment; Treatment Outcome | 2020 |
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2020 |
A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Injections, Subcutaneous; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Severity of Illness Index; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2021 |
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Paclitaxel; Remission Induction; Retrospective Studies; Tegafur; Vomiting | 2017 |
A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
Topics: Aged; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Incidence; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Treatment Outcome | 2017 |
A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Integrin alphaVbeta3; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Receptors, Vitronectin; Snake Venoms; Treatment Outcome | 2017 |
Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Research Design; Sirolimus; Thrombocytopenia | 2017 |
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Double-Blind Method; Female; Humans; Ipilimumab; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Paclitaxel; Proportional Hazards Models | 2017 |
Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Progression-Free Survival; Severity of Illness Index; Thrombocytopenia; Triple Negative Breast Neoplasms | 2018 |
Evaluation of the safety of ramucirumab in Japanese patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2018 |
Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
Topics: Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel | 2018 |
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prognosis; Progression-Free Survival; Prospective Studies; Retrospective Studies | 2019 |
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2013 |
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Everolimus; Exanthema; Female; Humans; Mastectomy, Segmental; Middle Aged; Mucositis; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Sirolimus; Thrombocytopenia; Treatment Outcome | 2013 |
A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Consolidation Chemotherapy; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Intention to Treat Analysis; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Severity of Illness Index; Survival Analysis | 2013 |
A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Paclitaxel; Thrombocytopenia; Urinary Bladder Neoplasms | 2013 |
A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Paclitaxel; Perioperative Care; Preoperative Care; Quality of Life; Treatment Outcome; Vomiting | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Topics: Administration, Intravenous; Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Time Factors; Treatment Outcome; Young Adult | 2013 |
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Pancreatic Neoplasms | 2013 |
A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Europe; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Placebos; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2013 |
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Paclitaxel; Platinum; Prospective Studies; Stomach Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Proportional Hazards Models; Treatment Outcome | 2014 |
Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Stomach Neoplasms; Treatment Outcome | 2014 |
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2014 |
A Phase II Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin for Inoperable Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Prospective Studies; Survival Rate | 2016 |
Exploration of paclitaxel (Taxol) as a treatment for malignant tumors in cats: a descriptive case series.
Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Diarrhea; Drug Administration Schedule; Infusions, Intravenous; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Vomiting | 2015 |
Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Tegafur; Uracil | 2014 |
Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Platinum; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study).
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; gamma-Glutamyltransferase; Humans; Indoles; Lymphopenia; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Treatment Outcome | 2014 |
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (A
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Fatigue; Female; Humans; Hypertension; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Thrombocytopenia; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Europe; Fatigue; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Middle Aged; Nausea; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Time Factors; Treatment Outcome; Vomiting; Young Adult | 2014 |
Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Risk Assessment; Risk Factors; Thrombocytopenia; Treatment Outcome | 2014 |
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Administration Schedule; Drug Eruptions; Fatigue; Female; Heterocyclic Compounds, 3-Ring; Humans; Hyperglycemia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Severity of Illness Index; Treatment Outcome | 2015 |
Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Disease-Free Survival; Female; Genital Neoplasms, Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Prospective Studies; Survival Rate | 2015 |
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cytoreduction Surgical Procedures; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Indoles; Intention to Treat Analysis; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Response Evaluation Criteria in Solid Tumors; Thrombocytopenia; Young Adult | 2016 |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Combinations; Edema; Fatigue; Female; Follow-Up Studies; Health Status; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Tegafur | 2016 |
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Topics: Aged; Anemia; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cancer Vaccines; Carboplatin; Carcinoma, Non-Small-Cell Lung; CD56 Antigen; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Fatigue; Female; Gemcitabine; Humans; Immunotherapy; Lectins, C-Type; Lung Neoplasms; Lymphocyte Activation; Lymphocytes; Male; Membrane Glycoproteins; Middle Aged; Mucin-1; Neutropenia; Paclitaxel; Pemetrexed; Predictive Value of Tests; Receptors, IgG | 2016 |
Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Fatigue; Female; Humans; Induction Chemotherapy; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Treatment Outcome | 2017 |
nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Canada; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Weekly vinorelbine and paclitaxel in older patients with advanced non-small cell lung cancer: A phase II Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Ischemia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy-Induced Febrile Neutropenia; Disease-Free Survival; Early Termination of Clinical Trials; Female; Heart Arrest; Humans; Hypoxia; Lung Neoplasms; Lymphopenia; Male; Neutropenia; Paclitaxel; Pneumonia; Quality of Life; Respiratory Insufficiency; Survival Rate; Tomography, X-Ray Computed; Vinblastine; Vinorelbine | 2017 |
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Cisplatin; Cyclophosphamide; Diarrhea; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Receptor, ErbB-2; Stroke Volume; Taxoids; Trastuzumab | 2016 |
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer.
Topics: Aged; Albumins; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2017 |
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Cell Survival; Chemistry, Pharmaceutical; Chromatography, Liquid; Cross-Over Studies; Female; Humans; Leukocyte Count; Linear Models; Male; Middle Aged; Models, Biological; Neoplasms; Neutropenia; Neutrophils; Paclitaxel; Stem Cells; Structure-Activity Relationship; Tandem Mass Spectrometry | 2009 |
Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Female; Humans; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Neoplasms; Neutropenia; Paclitaxel | 2008 |
A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome | 2009 |
Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 2009 |
[Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Neutropenia; Paclitaxel; Survival Rate; Vomiting; Young Adult | 2008 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2009 |
Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Penile Neoplasms; Stomatitis; Survival Rate; Treatment Outcome | 2009 |
Multi-center phase II trial of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric and gastro-esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2009 |
Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Urinary Bladder Neoplasms | 2009 |
A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Fever; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2009 |
Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Fever; Humans; Male; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Pain; Salvage Therapy; Severity of Illness Index; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2009 |
Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagitis; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Longitudinal Studies; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction; Survival Rate; Thrombocytopenia; Treatment Outcome | 2010 |
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diarrhea; Exanthema; Fatigue; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Pain; Skin Neoplasms; Survival Rate; Tumor Burden | 2009 |
Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pemetrexed; Peripheral Nervous System Diseases; Survival Analysis | 2010 |
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Receptors, TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome; Young Adult | 2009 |
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Epithelial Cells; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Proportional Hazards Models; Treatment Outcome; Young Adult | 2009 |
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Quality of Life; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine; Young Adult | 2009 |
Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Female; Fever; Humans; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Paclitaxel; Thrombocytopenia; Trastuzumab; Treatment Outcome | 2009 |
Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Treatment Outcome | 2010 |
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cytokines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Paclitaxel; Proliferating Cell Nuclear Antigen; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2010 |
A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lenalidomide; Male; Middle Aged; Nausea; Neutropenia; Orchiectomy; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Thalidomide; Treatment Outcome; Vomiting | 2010 |
Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Paclitaxel; Radiotherapy; Remission Induction; Uterine Cervical Neoplasms | 2010 |
Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Preoperative Care; Treatment Outcome | 2010 |
Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Time Factors; Young Adult | 2011 |
[Efficacy and safety assessment of neoadjuvant paclitaxel and trastuzumab in Chinese women with Her-2 positive operable breast cancer].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2010 |
Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Paclitaxel; Polymorphism, Genetic; Risk Factors; Survival Rate; Treatment Outcome | 2011 |
Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infections; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Phase II study of weekly paclitaxel, cisplatin, and 5-fluorouracil for advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Stomach Neoplasms | 2011 |
A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Tegafur; Thrombocytopenia; Treatment Outcome | 2011 |
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Leukopenia; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Neutropenia; Paclitaxel; Receptors, Estrogen; Treatment Outcome | 2012 |
Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Furans; Humans; Ketones; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence; Retreatment; Tubulin Modulators | 2012 |
A Phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for Stage III non-small cell lung cancer: WJTOG 3305.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Dose Fractionation, Radiation; Drug Administration Schedule; Esophagitis; Female; Fever; Humans; Injections, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Radiotherapy, Conformal; Tumor Burden | 2012 |
Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Area Under Curve; Brain; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Peptides; Treatment Outcome; Young Adult | 2012 |
Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; China; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome | 2011 |
[Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Endostatins; Endothelial Cells; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Quality of Life; Recombinant Proteins; Remission Induction; Vinblastine; Vinorelbine; Vomiting | 2011 |
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Hemorrhage; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Urologic Neoplasms; Urothelium | 2012 |
Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neutropenia; Paclitaxel; Radiation Pneumonitis; Treatment Outcome | 2012 |
Gemcitabine and paclitaxel combination as second-line chemotherapy in patients with small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Neutropenia; Paclitaxel; Small Cell Lung Carcinoma | 2013 |
Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Paclitaxel; Uterine Cervical Neoplasms | 2012 |
[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Docetaxel; Female; Hemorrhage; Humans; Hypertension; Middle Aged; Neutropenia; Paclitaxel; Proteinuria; Taxoids; Thromboembolism; Young Adult | 2012 |
Phase II study of paclitaxel in combination with carboplatin for patients with recurrent or persistent uterine sarcoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Sarcoma, Endometrial Stromal; Uterine Neoplasms | 2012 |
A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Piperazines; Pyrimidines; Radiotherapy, Adjuvant; Severity of Illness Index; Treatment Outcome | 2012 |
A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Frail Elderly; Humans; Imatinib Mesylate; Lung; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Paclitaxel; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Signal Transduction; Survival Analysis; Treatment Outcome | 2012 |
Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Aging; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome | 2013 |
Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neutropenia; Paclitaxel; Polyglutamic Acid; Proportional Hazards Models; Treatment Outcome | 2014 |
A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Fatigue; Female; Humans; Hypoalbuminemia; Hypokalemia; Hyponatremia; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Treatment Outcome | 2013 |
Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Induction Chemotherapy; Middle Aged; Nausea; Neoplasm Grading; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2013 |
[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Large-Core Needle; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lung Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Survival Rate; Young Adult | 2012 |
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Probability; Recombinant Proteins; Reference Values; Taxoids; Treatment Outcome | 2002 |
A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Female; Fever; Humans; Lymphopenia; Menopause; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Palliative Care; Prospective Studies; Safety; Taxoids; Treatment Outcome | 2002 |
Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Palliative Care; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2002 |
Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Doxorubicin; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Tamoxifen; Treatment Outcome | 2002 |
Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Molecular Structure; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 2002 |
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Analysis; Vomiting | 2002 |
Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Docetaxel; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pneumonia; Thrombocytopenia; Treatment Outcome | 2002 |
Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival; Treatment Outcome | 2002 |
Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost Control; Deoxycytidine; Disease Progression; Docetaxel; Drug Costs; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
Phase II study of paclitaxel (Genaxol) and cisplatin combination in treating Chinese patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Quality of Life; Survival; Vomiting | 2002 |
Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Incidence; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2002 |
A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Humans; Infections; Lung Neoplasms; Male; Neutropenia; Paclitaxel; Taxoids | 2002 |
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Double-Blind Method; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-3; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Recombinant Fusion Proteins; Recombinant Proteins; Taxoids; Treatment Outcome | 2002 |
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infections; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Palliative Care; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Delayed-Action Preparations; Docetaxel; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Neutrophils; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2003 |
Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Cyclosporine; Diarrhea; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Stomach Neoplasms; Treatment Outcome; Vomiting | 2003 |
Hyperfractionated radiotherapy and paclitaxel for locally advanced/unresectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Dose Fractionation, Radiation; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Patient Compliance; Prospective Studies; Radiation-Sensitizing Agents; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
A phase I study of carboplatin and docetaxel for advanced non-small cell lung cancer using the continual reassessment method.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia | 2002 |
Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Topotecan; Treatment Outcome | 2003 |
Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Prospective Studies; Thrombocytopenia; Treatment Outcome | 2003 |
Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System; Treatment Outcome | 2003 |
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome; Vidarabine | 2003 |
Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pulmonary Fibrosis; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Logistic Models; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Proportional Hazards Models; Recombinant Proteins; Survival Analysis | 2003 |
Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 2003 |
Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study.
Topics: Anemia; Antineoplastic Agents, Phytogenic; Child; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Neoplasms; Neutropenia; Paclitaxel; Patient Selection; Platelet Count | 2003 |
Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Erythrocyte Count; Female; Humans; Infusions, Intravenous; Middle Aged; Mouth Mucosa; Neutropenia; Ovarian Neoplasms; Paclitaxel; Radiation-Protective Agents; Stomatitis; Thrombocytopenia | 2003 |
Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer.
Topics: Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Count; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Middle Aged; Neutropenia; Paclitaxel; Razoxane; Recombinant Proteins | 2003 |
Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Topotecan | 2003 |
Paclitaxel, carboplatin, and oral etoposide in advanced gastric adenocarcinoma: association with severe myelotoxicity.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Etoposide; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Stomach Neoplasms; Treatment Failure | 2003 |
Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01).
Topics: Adult; Aged; Alopecia; Antiemetics; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Feasibility Studies; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Neutropenia; Paclitaxel; Ranitidine; Soft Tissue Neoplasms; Vomiting, Anticipatory | 2003 |
Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment-induced neutropenia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Genital Neoplasms, Female; Humans; Neutropenia; Paclitaxel | 2003 |
Comparison of neutropenia in a randomized, crossover trial of 3-, 6-, and 24-h infusions of paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Cross-Over Studies; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel | 2003 |
A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Neutropenia; Paclitaxel; Pilot Projects; Treatment Outcome | 2003 |
A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2003 |
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Stomatitis; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis | 2003 |
Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Estramustine; Etoposide; Fatigue; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Prostatic Neoplasms; Sepsis; Survival Analysis; Treatment Outcome | 2003 |
Biweekly paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Treatment Outcome | 2003 |
Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Urologic Neoplasms | 2004 |
Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Combined Modality Therapy; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Treatment Outcome | 2004 |
Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Topotecan | 2004 |
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Farnesyltranstransferase; Fatigue; Female; Heart Arrest; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Piperidines; Pyridines; Treatment Outcome | 2004 |
Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome | 2004 |
A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel | 2004 |
Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Quality of Life; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: a dose escalation study.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Hematologic Diseases; Hospitalization; Humans; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Thrombocytopenia; Treatment Outcome; Ventricular Function, Left | 2004 |
[Efficacy and safety of weekly taxol (TXL) for advanced recurrent breast cancer evaluated in a multi-center cooperative clinical trial].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel | 2004 |
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Treatment Outcome | 2004 |
Gemcitabine and vinorelbine as second-line therapy for non-small cell lung cancer after treatment with paclitaxel plus platinum.
Topics: Adult; Aftercare; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Platinum; Survival Rate; Vinblastine; Vinorelbine | 2004 |
A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lung; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2004 |
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Paclitaxel; Quality of Life | 2004 |
Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Sepsis; Survival Analysis; Treatment Outcome | 2004 |
Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Stomatitis; Treatment Outcome | 2004 |
Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedule; Female; Humans; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel | 2004 |
Cisplatin, paclitaxel and escalating doses of doxorubicin (TAP) in advanced ovarian cancer: a phase I trial.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administration Schedule; Female; Humans; Leukopenia; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Vomiting, Anticipatory | 2004 |
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Confidence Intervals; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neutropenia; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Proportional Hazards Models; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Clinical experience of weekly paclitaxel-based treatment as preoperative chemotherapy for patients with primary breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Treatment Outcome | 2004 |
[A tolerability study of A cremophor-free albumin bound nanoparticle paclitaxel intravenously administered in patients with advanced solid tumor].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Diplopia; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Nanotechnology; Nasopharyngeal Neoplasms; Neutropenia; Paclitaxel | 2004 |
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Greece; Humans; Middle Aged; Neutropenia; Paclitaxel; Trastuzumab; Treatment Outcome | 2004 |
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Vomiting | 2005 |
Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neutropenia; Paclitaxel; Severity of Illness Index; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2005 |
A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel | 2004 |
Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. A single institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Female; Heart Diseases; Humans; Infusions, Intravenous; Neutropenia; Paclitaxel; Survival Analysis | 2005 |
Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors.
Topics: Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Polyglutamic Acid; Taxoids; Thrombocytopenia; Treatment Failure | 2005 |
Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia; Urinary Bladder Neoplasms; Urothelium | 2005 |
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose Fractionation, Radiation; Follow-Up Studies; Head and Neck Neoplasms; Humans; Nausea; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Prospective Studies; Retreatment; Salvage Therapy; Stomatitis; Vomiting | 2005 |
[Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Survival Rate | 2004 |
A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neuroprotective Agents; Neutropenia; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2005 |
Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Endpoint Determination; Humans; Leukopenia; Lung Neoplasms; Neoplasm Staging; Neutropenia; Paclitaxel; Prospective Studies; Survival Rate | 2005 |
Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Drug Administration Schedule; Endpoint Determination; Female; Fluorouracil; Humans; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Platinum; Stomach Neoplasms | 2005 |
[Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction | 2005 |
Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Stomach Neoplasms; Survival Rate | 2005 |
A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Arthralgia; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Polyethylene Glycols | 2005 |
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cathepsins; Combined Modality Therapy; Cyclosporine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Male; Mice; Middle Aged; Neutropenia; Paclitaxel; Prostatic Neoplasms; Radioimmunotherapy; Soft Tissue Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2005 |
Gemcitabine and paclitaxel in metastatic or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel | 2005 |
Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Neoplasm; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chelating Agents; Clinical Trials as Topic; Disease Progression; Edetic Acid; Female; Glycoproteins; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Pentetic Acid; Radioimmunotherapy; Radiometry; Thrombocytopenia; Treatment Outcome; Up-Regulation; Yttrium Radioisotopes | 2005 |
Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Time Factors | 2005 |
Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel | 2006 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mucositis; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Patient Compliance; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction; Spain; Survival Analysis; Treatment Outcome | 2005 |
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
Topics: Adult; Aged; Algorithms; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boston; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Darbepoetin alfa; Doxorubicin; Erythrocyte Transfusion; Erythropoietin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome | 2005 |
Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Vomiting, Anticipatory | 2005 |
[A phase I study of combination chemotherapy using TS-1 and weekly paclitaxel for advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur | 2006 |
Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Paclitaxel; Prognosis; Risk Factors; Survival Rate; Thrombocytopenia; Treatment Outcome | 2006 |
Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Multivariate Analysis; Neutropenia; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Drug Administration Schedule; Female; Headache; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2006 |
[Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Arthralgia; Blood Cell Count; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Neutrophils; Paclitaxel; Polyethylene Glycols; Recombinant Proteins | 2006 |
[Carboplatin plus gemcitabine therapy versus carboplatin plus weekly paclitaxel therapy for advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia | 2006 |
Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Salvage Therapy; Survival Rate | 2006 |
[Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins | 2006 |
Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Neoplasm Metastasis; Neutropenia; Paclitaxel; Salvage Therapy; Vinblastine; Vinorelbine | 2007 |
[Adjuvant doxorubicin and cyclophosphamide followed by weekly paclitaxel for Japanese women with node-positive breast cancer: a multi-institutional feasibility study in a variety of practice settings in Kyushu].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neutropenia; Paclitaxel; Vomiting, Anticipatory | 2006 |
[Combined chemotherapy with weekly paclitaxel and carboplatin for recurrent and refractory epithelial ovarian cancer--phase I study].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel | 2006 |
Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Diarrhea; Drug Administration Schedule; Epirubicin; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Paclitaxel; Patient Compliance; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2006 |
Paclitacxel and carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Paclitaxel; Thrombocytopenia; Tomography, X-Ray Computed; Treatment Outcome; Vomiting | 2006 |
Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Dose-Response Relationship, Drug; Female; Fever; Half-Life; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Treatment Outcome | 2007 |
Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Remission Induction; Thrombocytopenia; Topotecan; Treatment Outcome | 2007 |
Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Female; Fever; Follow-Up Studies; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recurrence; Stomach Neoplasms; Survival Rate | 2007 |
Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Arthralgia; Carcinoma, Squamous Cell; Drug Administration Schedule; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome | 2007 |
Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Topotecan | 2006 |
Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate | 2006 |
Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Paclitaxel; Probability; Prognosis; Risk Factors; Survival Analysis; Topotecan | 2006 |
A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Odds Ratio; Paclitaxel; Patient Selection; Probability; Prognosis; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome; United States | 2006 |
A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Polyethylene Glycols; Survival Rate | 2007 |
Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Female; Fever; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organoplatinum Compounds; Paclitaxel; Severity of Illness Index; Treatment Outcome | 2008 |
A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Fever; Foot Dermatoses; Hand Dermatoses; Humans; Liposomes; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Paresthesia; Polyethylene Glycols; Salvage Therapy; Treatment Outcome | 2008 |
Granulocyte-colony stimulating factors for secondary prevention of leucopenia in patients receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Cisplatin; Female; Genital Neoplasms, Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Risk Factors | 2006 |
[Nadaplatin or cisplatin combined with paclitaxol in treatment for non-small cell lung cancer: a randomized controlled study].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Paclitaxel; Prospective Studies; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2007 |
[Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fatigue; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prospective Studies; Radiotherapy; Radiotherapy, High-Energy; Survival Analysis | 2007 |
Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer.
Topics: Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Teniposide | 2008 |
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Rate | 2008 |
[Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; Fever; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Topotecan; Treatment Outcome | 2007 |
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Floxuridine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Tegafur; Thrombocytopenia | 2008 |
A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Topics: Adenocarcinoma; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Combinations; Female; Gastrointestinal Diseases; Humans; Hyponatremia; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Analysis; Tegafur | 2008 |
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Analysis | 1996 |
Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary report.
Topics: Adult; Aged; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins | 1993 |
Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapy.
Topics: Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1994 |
A phase II trial of paclitaxel (Taxol) in advanced esophageal cancer: preliminary report.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Treatment Outcome | 1994 |
A phase I trial of paclitaxel and etoposide for metastatic or recurrent malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia | 1995 |
Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chi-Square Distribution; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; National Institutes of Health (U.S.); Neoplasm Metastasis; Neutropenia; Paclitaxel; Referral and Consultation; Remission Induction; United States | 1995 |
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Cohort Studies; Disease Progression; Drug Resistance; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Middle Aged; Netherlands; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Safety; Thrombocytopenia | 1995 |
Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Resistance; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction | 1995 |
Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Care Facilities; Carcinoma; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Texas | 1995 |
Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Muscle, Skeletal; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Survival Rate; Thrombocytopenia | 1995 |
Four-day paclitaxel infusion with cisplatin for patients with lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Tumor Cells, Cultured | 1995 |
Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Cohort Studies; Creatinine; Dose-Response Relationship, Drug; Drug Tolerance; Filgrastim; Glomerular Filtration Rate; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Thrombocytopenia | 1995 |
A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cohort Studies; Drug Tolerance; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Thrombocytopenia | 1995 |
Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.
Topics: Adult; Aged; Alopecia; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Palliative Care; Vomiting | 1995 |
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Thrombocytopenia; Topotecan; United States | 1995 |
Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel | 1995 |
Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer. European Lung Cancer Working Party.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel | 1995 |
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distribution; Doxorubicin; Drug Administration Schedule; Female; Heart; Heart Failure; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction | 1995 |
Biweekly paclitaxel and cisplatin: a phase I/II study in the first-line treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Female; Humans; Neutropenia; Paclitaxel; Remission Induction | 1995 |
Interim results of a phase I/II study of biweekly paclitaxel and cisplatin in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction | 1995 |
Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cross-Over Studies; Disease Progression; Female; Humans; Infusions, Intravenous; Middle Aged; Mitomycins; Neoplasm Metastasis; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Remission Induction | 1995 |
A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Colorado; Dose-Response Relationship, Drug; Drug Tolerance; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Safety | 1995 |
Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Esophagitis; Feasibility Studies; Female; Humans; Infusions, Intravenous; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Radiotherapy; Radiotherapy Dosage; Remission Induction; Thorax | 1995 |
Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Tolerance; Feasibility Studies; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Paclitaxel; Thrombocytopenia; Vomiting | 1995 |
Preliminary analysis of a phase II study of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Drug Tolerance; Esophagitis; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Radiotherapy; Radiotherapy Dosage; Remission Induction | 1995 |
Paclitaxel by 1-hour infusion in combination chemotherapy of stage III non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Esophagitis; Etoposide; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Leukopenia; Lung Neoplasms; Neoplasm Staging; Neutropenia; Paclitaxel; Radiotherapy; Remission Induction | 1995 |
Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Sensation Disorders; Thrombocytopenia | 1995 |
Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Treatment Outcome | 1993 |
Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.
Topics: Aged; Breast Neoplasms; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Time Factors | 1995 |
Primary therapy of multiple myeloma with paclitaxel (taxol).
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neutropenia; Paclitaxel; Remission Induction | 1994 |
Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Prednisone; Premedication; Survival Rate; Taxoids | 1995 |
Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer.
Topics: Dexamethasone; Diphenhydramine; Drug Administration Schedule; Female; Humans; Injections, Intraperitoneal; Neutropenia; Ovarian Neoplasms; Paclitaxel; Premedication; Ranitidine; Treatment Outcome | 1994 |
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Hypersensitivity; Drug Resistance; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids | 1995 |
Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Remission Induction; Salvage Therapy; Survival Rate; United States | 1994 |
[Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug].
Topics: Adolescent; Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 1994 |
A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Eruptions; Europe; Female; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1994 |
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Asthenia; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Europe; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1994 |
Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines.
Topics: Adult; Alopecia; Antibiotics, Antineoplastic; Breast Neoplasms; Chemotherapy, Adjuvant; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1994 |
Paclitaxel (Taxol): phase I/II trial comparing 1-hour infusion schedules.
Topics: Adult; Aged; Alopecia; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Prospective Studies; Thrombocytopenia; Time Factors; Treatment Outcome | 1994 |
Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1994 |
[An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Colonic Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Stomach Neoplasms; Taxoids | 1994 |
[Phase II clinical study of RP56976 (docetaxel) in patients with carcinoma ovarii or carcinoma colli uteri].
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cystadenocarcinoma, Serous; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids; Thrombocytopenia; Uterine Cervical Neoplasms | 1994 |
Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carboplatin; Cisplatin; Docetaxel; Drug Resistance; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Analysis; Taxoids | 1994 |
Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Esophagitis; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Radiotherapy Dosage | 1994 |
Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group.
Topics: Blood Pressure; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Premedication | 1993 |
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Carcinoma, Medullary; Carcinoma, Papillary; Docetaxel; Female; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids; Toxicity Tests | 1996 |
Docetaxel (Taxotere): an overview of first-line monotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 1995 |
Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Thrombocytopenia | 1996 |
Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Uterine Cervical Neoplasms | 1996 |
A Phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel | 1996 |
Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fever; Heart Diseases; Humans; Middle Aged; Neutropenia; Paclitaxel | 1996 |
Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Feasibility Studies; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Remission Induction | 1996 |
Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Neutropenia; Paclitaxel; Remission Induction | 1996 |
A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Prospective Studies; Remission Induction; Sarcoma; Thrombocytopenia | 1995 |
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Treatment Failure | 1996 |
Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Premedication; Remission Induction | 1995 |
Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Axons; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction | 1995 |
Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.
Topics: Ambulatory Care; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Hypersensitivity; Esophagitis; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Neutropenia; Paclitaxel; Premedication; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, High-Energy; Remission Induction | 1995 |
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Sepsis; Topotecan | 1996 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Tolerance; Expectorants; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Vinblastine; Vinorelbine | 1996 |
Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Tolerance; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Leukocyte Count; Male; Mesna; Middle Aged; Neoplasms; Neutropenia; Neutrophils; Paclitaxel; Recombinant Proteins; Remission Induction | 1996 |
Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology group (ECOG) results.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Female; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel | 1995 |
Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bone Marrow Transplantation; Breast Neoplasms; Carmustine; Cisplatin; Creatinine; Cyclophosphamide; Dose-Response Relationship, Drug; Electrolytes; Female; Hematopoiesis; Humans; Kidney Function Tests; Neoplasm Metastasis; Neutropenia; Paclitaxel; Renal Insufficiency; Risk Factors; Transplantation, Autologous | 1996 |
An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cross-Over Studies; Disease Progression; Doxorubicin; Europe; Female; Heart Failure; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Prospective Studies; Remission Induction | 1996 |
A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Muscular Diseases; Neutropenia; Paclitaxel; Pain; Peripheral Nervous System Diseases; Remission Induction; Stroke Volume; Ventricular Function, Left | 1996 |
A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Drug Tolerance; Epirubicin; Feasibility Studies; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart; Heart Failure; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Recombinant Proteins; Remission Induction; Stroke Volume; Ventricular Function, Left | 1996 |
Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mucous Membrane; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Time Factors; Vinblastine; Vinorelbine | 1996 |
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Vomiting | 1997 |
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis | 1997 |
Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: a University of Colorado Cancer Center study.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia | 1996 |
The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 1996 |
Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Thrombocytopenia; Treatment Outcome; Vomiting | 1996 |
Phase I/II trial of weekly paclitaxel in patients with advanced lung cancer.
Topics: Alopecia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Eruptions; Drug Tolerance; Humans; Lung Diseases; Lung Neoplasms; Muscular Diseases; Neoplasm Metastasis; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases | 1996 |
Paclitaxel and carboplatin in inoperable non-small cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Muscular Diseases; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Rate; Thrombocytopenia; Treatment Outcome | 1996 |
Paclitaxel and carboplatin: a phase I study in advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Steroids; Treatment Outcome | 1996 |
Preliminary results of a dose-finding study of paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Tolerance; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 1996 |
Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carcinoma, Non-Small-Cell Lung; Confusion; Dexamethasone; Diphenhydramine; Drug Tolerance; Female; Hematuria; Humans; Ifosfamide; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Muscular Diseases; Neutropenia; Paclitaxel; Paresthesia; Survival Rate; Treatment Outcome | 1996 |
Chemoradiotherapy in non-small cell lung cancer: paclitaxel/carboplatin/radiotherapy in regionally advanced disease.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Humans; Lung Neoplasms; Middle Aged; Mucous Membrane; Neutropenia; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate | 1996 |
Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Taxoids | 1996 |
Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Interleukin-3; Leukocyte Count; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platelet Count | 1997 |
Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia | 1997 |
Clinical pharmacology of carboplatin administered in combination with paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1997 |
Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Humans; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Remission Induction; Stomach Neoplasms; Tomography, X-Ray Computed | 1997 |
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; CA-125 Antigen; Cisplatin; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Carriers; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Liposomes; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Ulcer | 1997 |
Experience at the Istituto Nazionale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Neutropenia; Paclitaxel; Recombinant Proteins | 1997 |
Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiac Output, Low; Cyclophosphamide; Epirubicin; Female; France; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1997 |
Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1997 |
Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiac Output, Low; Female; Humans; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 1997 |
A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neutropenia; Paclitaxel; Survival | 1997 |
A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Cohort Studies; Combined Modality Therapy; Female; Fever; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neutropenia; Paclitaxel; Preoperative Care; Survival Rate; Thrombocytopenia | 1997 |
Chemoprophylaxis with ciprofloxacin in ovarian cancer patients receiving paclitaxel: a randomized trial.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Antineoplastic Agents, Phytogenic; Bacterial Infections; Ciprofloxacin; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1997 |
Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Disease Progression; Female; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Thrombocytopenia | 1997 |
Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma; Cisplatin; Disease Progression; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Recombinant Proteins | 1997 |
Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cisplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Salvage Therapy; Treatment Failure | 1997 |
Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Survival Analysis; Treatment Failure; Treatment Outcome; Vinblastine; Vinorelbine | 1997 |
Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 1997 |
Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Docetaxel; Drug Administration Schedule; Female; Humans; Incidence; Infant; Infusions, Intravenous; Male; Neoplasms; Neutropenia; Paclitaxel; Severity of Illness Index; Taxoids; Treatment Outcome | 1997 |
Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Neutropenia; Paclitaxel; Treatment Outcome | 1997 |
Docetaxel in combination with doxorubicin: a phase I dose-finding study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pilot Projects; Survival Rate; Taxoids | 1997 |
Docetaxel and cyclophosphamide in patients with advanced solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Humans; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 1997 |
Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pilot Projects; Taxoids | 1997 |
Docetaxel combined with vinorelbine: phase I results and new study designs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Liver Neoplasms; Neoplasm Metastasis; Neutropenia; Paclitaxel; Research Design; Taxoids; Vinblastine; Vinorelbine | 1997 |
Docetaxel in combination with fluorouracil: study design and preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Taxoids | 1997 |
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Heart Diseases; Humans; Least-Squares Analysis; Middle Aged; Neutropenia; Paclitaxel; Prospective Studies; Stroke Volume; Survival Analysis; Treatment Outcome | 1997 |
Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Thrombocytopenia | 1997 |
Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Cisplatin; Confidence Intervals; Disease Progression; Female; France; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Safety; Survival Rate; Thrombocytopenia; Treatment Outcome | 1997 |
Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Arthralgia; Carboplatin; Dose-Response Relationship, Drug; Female; Germany; Humans; Infusions, Intravenous; Middle Aged; Neoplasm, Residual; Neutropenia; Ovarian Neoplasms; Paclitaxel; Pain; Patient Selection; Peripheral Nervous System Diseases; Prospective Studies; Quality of Life; Remission Induction; Retrospective Studies; Single-Blind Method; Survival Rate; Thrombocytopenia; Vomiting | 1997 |
Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
Topics: Adult; Aged; Ambulatory Care; Anemia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Argentina; Biomarkers, Tumor; CA-125 Antigen; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Microtubules; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Premedication; Remission Induction; Survival Rate; Thrombocytopenia; Vomiting | 1997 |
Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Incidence; Infusions, Intravenous; Laparotomy; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Reoperation; Spain; Survival Rate; Thrombocytopenia; Treatment Outcome | 1997 |
Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cause of Death; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Greece; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Remission Induction; Survival Rate; Thrombocytopenia | 1997 |
Salvage weekly paclitaxel in recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; CA-125 Antigen; Cohort Studies; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fever; Follow-Up Studies; Hospitalization; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Remission Induction; Retrospective Studies; Salvage Therapy; Tomography, X-Ray Computed | 1997 |
Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Transitional Cell; Confidence Intervals; Disease Progression; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leucovorin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neutropenia; Paclitaxel; Remission Induction; Salvage Therapy; Sepsis; Urinary Bladder Neoplasms | 1997 |
Metastatic breast cancer: treatment with fluorouracil-based combinations.
Topics: Adult; Aged; Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Nausea; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 1997 |
Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Doxorubicin; Drug Administration Schedule; Estrogen Antagonists; Female; Fever; Humans; Infusions, Intravenous; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Tamoxifen; Taxoids | 1997 |
Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bacterial Infections; Breast Neoplasms; Cause of Death; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fever; Heart Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Quality of Life; Remission Induction; Safety; Survival Rate; Taxoids; Thrombocytopenia | 1997 |
Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclophosphamide; Dexamethasone; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Premedication; Remission Induction; Sarcoma; Taxoids | 1997 |
Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fever; Heart Failure; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1997 |
Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas.
Topics: Adult; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Female; Humans; Injections, Intravenous; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oligodendroglioma; Paclitaxel; Procarbazine; Salvage Therapy; Thrombocytopenia; Vincristine | 1997 |
Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Tolerance; Female; Humans; Neutropenia; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Thrombocytopenia | 1997 |
Tolerance of paclitaxel 3-hour infusion with and without granulocyte colony-stimulating factor on a biweekly schedule.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome | 1997 |
Phase I trial of weekly paclitaxel in advanced lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neutropenia; Paclitaxel | 1998 |
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bayes Theorem; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Edema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Prospective Studies; Taxoids | 1998 |
Phase I study of vinorelbine and paclitaxel in small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nervous System; Neutropenia; Paclitaxel; Thrombocytopenia; Vinblastine | 1997 |
A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1998 |
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Vomiting | 1998 |
Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids | 1997 |
Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Female; Hematopoietic Stem Cell Mobilization; Humans; Melphalan; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neutropenia; Paclitaxel; Thiotepa; Treatment Outcome | 1998 |
Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids; Thrombocytopenia; Treatment Failure; Tumor Cells, Cultured | 1998 |
Paclitaxel, cisplatin, etoposide combination chemotherapy: a multifractionated bolus dose schedule for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 1998 |
Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel | 1998 |
Phase II trial of paclitaxel in patients with soft-tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Sarcoma | 1998 |
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Treatment Outcome | 1998 |
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Edema; Female; Fever; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Taxoids | 1998 |
Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.
Topics: Adult; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Glycerol; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel | 1998 |
Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Disease Progression; Docetaxel; Drug Administration Schedule; Edema; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Urologic Neoplasms | 1998 |
First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Patient Compliance; Recombinant Proteins; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
A phase II trial and pharmacokinetic analysis of 96-hour infusional paclitaxel in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1998 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1999 |
Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Female; Glioblastoma; Humans; Lung Neoplasms; Lymphocytes; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Pelvic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Survival Analysis; Taxoids; Treatment Outcome | 1999 |
The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen: a phase I-II study of paclitaxel, cisplatin, and vinorelbine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Vinblastine; Vinorelbine | 1999 |
Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 1998 |
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan | 1999 |
Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lymphocyte Count; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Ventricular Function, Left | 1999 |
Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Half-Life; Humans; Middle Aged; Neutropenia; Paclitaxel; Razoxane; Remission Induction; Ventricular Function, Left | 1999 |
Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial.
Topics: Adolescent; Adult; Child; Child, Preschool; Docetaxel; Dose-Response Relationship, Drug; Drug Eruptions; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Infant; Male; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids | 1999 |
Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Vinblastine; Vinorelbine | 1999 |
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Health Status; Humans; Middle Aged; Mitomycins; Neutropenia; Paclitaxel; Patient Compliance; Proportional Hazards Models; Prospective Studies; Survival Analysis; Taxoids; Thrombocytopenia; Vinblastine | 1999 |
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Quinazolines; Thiophenes | 1999 |
Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 1999 |
Phase II of doxorubicin/taxol in metastatic breast cancer. Argentine Multicenter Taxol Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Argentina; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Treatment Outcome | 1999 |
Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; United States | 1999 |
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neutropenia; Paclitaxel; Prospective Studies | 1999 |
Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomiz
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Combined Modality Therapy; Drug Synergism; Epirubicin; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Statistics, Nonparametric; Treatment Outcome | 1999 |
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bilirubin; Capecitabine; Cohort Studies; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia | 1999 |
Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1999 |
Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Vomiting | 1999 |
Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Prednisone; Quality of Life | 1999 |
Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Uterine Cervical Neoplasms | 1999 |
Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Time Factors | 1999 |
A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Time Factors | 1999 |
A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cohort Studies; Drug Administration Schedule; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia | 1999 |
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome | 2000 |
Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neutropenia; Paclitaxel; Taxoids | 1999 |
Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasms; Nervous System Diseases; Neutropenia; Outpatients; Paclitaxel; Taxoids; Thrombocytopenia | 2000 |
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Breast Neoplasms, Male; Chemical and Drug Induced Liver Injury; Docetaxel; Drug Resistance, Neoplasm; Female; Fever; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Paclitaxel; Prognosis; Risk Factors; Stomatitis; Taxoids; Treatment Outcome | 2000 |
A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Methylprednisolone; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2000 |
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Alopecia; Antineoplastic Agents, Phytogenic; Area Under Curve; Aspartate Aminotransferases; Breast Neoplasms; Diarrhea; Docetaxel; Fatigue; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Mouth Mucosa; Neoplasms; Neutropenia; Paclitaxel; Stomatitis; Taxoids; Time Factors | 2000 |
Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.
Topics: Adult; Antigens, CD34; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematocrit; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Middle Aged; Neutropenia; Paclitaxel; Platelet Count; Recombinant Proteins; Thrombocytopenia; Time Factors | 2000 |
Phase I study of cisplatin and docetaxel plus mitomycin C in patients with metastatic non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neutropenia; Paclitaxel; Taxoids | 1999 |
[Evaluation of paclitaxel and carboplatin in patients with endometrial cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Evaluation; Endometrial Neoplasms; Female; Humans; Leukopenia; Middle Aged; Neutropenia; Paclitaxel | 2000 |
The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan | 2000 |
Intestinal side-effects of docetaxel/vinorelbine combination.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastroenteritis; Humans; Neutropenia; Paclitaxel; Risk Factors; Taxoids; Vinblastine; Vinorelbine | 2000 |
[Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy. French Group of Pneumo-Cancerology].
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diosmin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Prednisolone; Premedication; Taxoids; Time Factors | 2000 |
A phase I trial of 96-hour paclitaxel infusion plus accelerated radiotherapy of unrespectable head and neck cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Drug Eruptions; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Radiation-Sensitizing Agents; Stomatitis | 1999 |
Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Recurrence; Taxoids | 2000 |
Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cohort Studies; Dexamethasone; Docetaxel; Drug Resistance, Neoplasm; Female; Glucocorticoids; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Prednisone; Taxoids | 2000 |
Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Nervous System Diseases; Neutropenia; Paclitaxel; Platelet Count; Radiation-Sensitizing Agents | 2000 |
The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzazepines; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Male; Middle Aged; Mouth Mucosa; Neoplasms; Neutropenia; Paclitaxel; Quinolines; Stomatitis; Taxoids; Vomiting | 2000 |
Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome | 2000 |
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cross-Over Studies; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Humans; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2000 |
A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Docetaxel; Female; Fever; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Water-Electrolyte Balance | 2000 |
Vinorelbine combined with paclitaxel infused over 96 hours (VI-TA-96) for patients with metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Economics, Pharmaceutical; Female; Fever; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biotransformation; Capecitabine; Carboxylic Ester Hydrolases; Deamination; Deoxycytidine; Dexamethasone; Docetaxel; Drug Administration Schedule; Female; Fever; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Liver; Male; Maximum Tolerated Dose; Methylprednisolone; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Paronychia; Prodrugs; Remission Induction; Taxoids; Treatment Outcome | 2000 |
Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Feasibility Studies; Female; Humans; Irinotecan; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pleural Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2000 |
[A phase II clinical study of China-made paclitaxel in the treatment of cancer patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1998 |
Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Thrombocytopenia | 2000 |
Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Microtubules; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 2000 |
A phase II trial of paclitaxel and epirubicin in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Ventricular Dysfunction, Left | 2000 |
Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Confidence Intervals; Disease Progression; Docetaxel; Female; Fever; Follow-Up Studies; Gastrectomy; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2000 |
Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Deoxycytidine; Diarrhea; Esophageal Neoplasms; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Paresthesia; Urinary Bladder Neoplasms; Vomiting | 2000 |
Interim results of a phase III trial. Paclitaxel/carboplatin vs paclitaxel/gemcitabine in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Analysis; Taxoids | 2000 |
A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia | 2000 |
A multicentre phase II pilot study of epirubicin and Taxol (paclitaxel) in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Female; Heart Function Tests; Humans; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome | 2000 |
Dose-finding study of paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Survival Rate | 2000 |
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Chromatography, High Pressure Liquid; Cross-Over Studies; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Time Factors | 2000 |
Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclosporins; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; Disease Progression; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Interstitial; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Stomatitis; Survival Analysis; Taxoids; Thiotepa; Thrombocytopenia; Transplantation Conditioning | 2000 |
Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Epithelium; Feasibility Studies; Female; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Survival Rate; Topotecan; Vomiting | 2000 |
Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome; Vomiting | 2000 |
A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fever; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Salvage Therapy; Taxoids | 2000 |
Phase I-II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB-IV non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 2000 |
A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fever; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2000 |
Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fever; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome | 2000 |
Docetaxel in patients with anthracycline-resistant advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel | 2001 |
Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel | 2001 |
Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Stomatitis; Topotecan | 2001 |
A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Epirubicin; Fatigue; Female; Fluorouracil; Glutathione; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leucovorin; Male; Middle Aged; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Thrombocytopenia; Treatment Outcome | 2001 |
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Regression Analysis; Thiotepa; Time Factors | 2001 |
Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms | 2001 |
Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2001 |
Absence of major peripheral neuropathy in a phase II trial of ifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Ifosfamide; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Platinum Compounds; Vinblastine; Vinorelbine | 2001 |
Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Heart; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Thrombocytopenia | 2001 |
Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genital Neoplasms, Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Infusions, Intravenous; Methylurea Compounds; Middle Aged; Neutropenia; Paclitaxel; Pelvic Neoplasms | 2001 |
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2001 |
Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagitis; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate | 2001 |
A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors.
Topics: Adenoma, Islet Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoid Tumor; Disease Progression; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2001 |
Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interactions; Epirubicin; Female; Humans; Myocardium; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
[Dose finding study of paclitaxel and carboplatin for ovarian cancer (JKTB)].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel | 2001 |
A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Topotecan | 2001 |
Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2001 |
Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Paclitaxel; Prognosis; Treatment Outcome | 2001 |
A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer.
Topics: Adult; Antigens, CD34; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Leukocyte Count; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Stem Cells; Taxoids | 2001 |
A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 2001 |
Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Taxoids | 2001 |
A phase I study of weekly docetaxel and cisplatin in advanced non-small cell lung cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Fever; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia | 2001 |
A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel | 2001 |
[Evaluation of efficacy and toxicity of docetaxel (Taxotere) in patients with advanced mammary gland cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Treatment Outcome | 2001 |
Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mitoxantrone; Nausea; Neutropenia; Paclitaxel; Sepsis; Survival Rate; Taxoids | 2001 |
Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2001 |
[Effect of weekly docetaxel in patients with recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pilot Projects; Taxoids | 2001 |
Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infections; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome | 2001 |
Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2001 |
Phase I trial of weekly docetaxel combined with cisplatin in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyponatremia; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Treatment Outcome | 2001 |
Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis | 2001 |
Mechanism-based pharmacokinetic model for paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Doxorubicin; Female; Glycerol; Humans; Infusions, Intravenous; Male; Mathematics; Middle Aged; Neutropenia; Paclitaxel; Solvents | 2001 |
Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis | 2001 |
Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Quality of Life; Treatment Outcome | 2001 |
Macrophage colony-stimulating factor prevents febrile neutropenia induced by chemotherapy.
Topics: Adolescent; Adult; Carboplatin; Female; Fever; Granulocytes; Humans; Macrophage Colony-Stimulating Factor; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Time Factors | 2001 |
Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical acti
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Anus Neoplasms; Carcinoma, Squamous Cell; Castor Oil; Chemistry, Pharmaceutical; Female; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neutropenia; Paclitaxel; Particle Size; Surface-Active Agents; Treatment Outcome | 2001 |
Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2001 |
Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome; Vinblastine | 2001 |
Weekly docetaxel (Taxotere) in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Skin Neoplasms; Taxoids; Temozolomide; Thrombocytopenia | 2002 |
Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Drug Administration Schedule; Female; Glycerol; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Surface-Active Agents; Thrombocytopenia; Time Factors | 2002 |
Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dermatitis; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia | 2001 |
A phase II study of paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Humans; Hypotension; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2001 |
Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Delayed-Action Preparations; Docetaxel; Double-Blind Method; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neutropenia; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 2002 |
Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Hypersensitivity; Female; Humans; Leukopenia; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Survival Rate; Vomiting | 2002 |
Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nervous System; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 2002 |
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Heart; Humans; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome | 2000 |
Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
A feasibility study of paclitaxel 225 mg/m(2) and carboplatin AUC = 6 in untreated advanced non-small cell lung cancer patients in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Feasibility Studies; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel | 2002 |
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fever; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Prospective Studies; Survival Analysis; Treatment Outcome | 2002 |
Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leiomyosarcoma; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome; Uterine Neoplasms | 2002 |
Sequences of taxol and cisplatin: a phase I and pharmacologic study.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Cisplatin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Microtubules; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases | 1991 |
151 other study(ies) available for paclitaxel and Neutropenia
| Article | Year |
|---|---|
Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity.
Topics: Animals; Antineoplastic Agents; Body Weight; Drug Evaluation, Preclinical; Heterocyclic Compounds, 4 or More Rings; Mice; Molecular Mimicry; Neoplasms, Experimental; Neutropenia; Ornithine-Oxo-Acid Transaminase; Oxazoles; Transplantation, Heterologous; Treatment Outcome | 2007 |
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Nanoconjugates; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies | 2021 |
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2021 |
GSTP1 c.313A > G mutation is an independent risk factor for neutropenia hematotoxicity induced by anthracycline-/paclitaxel-based chemotherapy in breast cancer patients.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Female; Genotype; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Mutation; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors | 2022 |
Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Genetic Variation; HeLa Cells; Humans; Japan; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Nanoparticles; Neutropenia; Paclitaxel | 2022 |
[Evaluation of Neutropenia and Usages of Antihypertensive Drugs in Patients Treated with Ramucirumab plus Paclitaxel Therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Ramucirumab; Retrospective Studies; Stomach Neoplasms | 2022 |
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.
Topics: Adenosine Diphosphate Ribose; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tubes; Female; Humans; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Retrospective Studies; Thrombocytopenia | 2023 |
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppression Therapy; Leukocytes, Mononuclear; Mice; Mice, Inbred C57BL; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Tumor Microenvironment | 2023 |
Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bone Marrow; Female; Humans; Male; Middle Aged; Neutropenia; Neutrophils; Paclitaxel; Retrospective Studies | 2019 |
Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome | 2020 |
Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Neutropenia; Paclitaxel; Peritoneal Neoplasms; Prognosis; Ramucirumab; Retrospective Studies; Stomach Neoplasms; Survival Rate | 2020 |
A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Exanthema; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2020 |
Toxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective cohort study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Doxorubicin; Ethiopia; Female; Humans; Middle Aged; Nausea; Neutropenia; Paclitaxel; Prospective Studies | 2020 |
Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors | 2021 |
Reinforcement learning and Bayesian data assimilation for model-informed precision dosing in oncology.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bayes Theorem; Biomarkers, Pharmacological; Clinical Decision Rules; Computer Simulation; Drug Development; Drug Discovery; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Learning; Male; Maximum Tolerated Dose; Medical Oncology; Middle Aged; Neutropenia; Paclitaxel; Patient Reported Outcome Measures; Quality Improvement; Reinforcement, Psychology; Safety; Treatment Outcome; Uncertainty | 2021 |
A whole-body circulatory neutrophil model with application to predicting clinical neutropenia from in vitro studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase I as Topic; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Agents; Hematopoiesis; Humans; Leukocyte Count; Models, Biological; Neutropenia; Neutrophils; Paclitaxel; Polyethylene Glycols | 2021 |
Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Survival Rate; Treatment Outcome | 2021 |
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Topics: Adult; Aged; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions.
Topics: Adult; Aged; Albumins; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Drug Hypersensitivity; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Retreatment; Retrospective Studies; Taxoids; Thrombocytopenia | 2017 |
Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.
Topics: Adenocarcinoma, Clear Cell; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2017 |
Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Treatment Outcome | 2017 |
Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carboplatin; Cytochrome P-450 CYP3A; Female; Humans; Leukocyte Count; Middle Aged; Neutropenia; Neutrophils; Outpatients; Ovarian Neoplasms; Paclitaxel; Uterine Cervical Neoplasms; Uterine Neoplasms | 2018 |
Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Organs at Risk; Paclitaxel; Probability; Radiation Dosage; Retrospective Studies; ROC Curve; Small Cell Lung Carcinoma; Thoracic Vertebrae | 2018 |
TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; China; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Treatment Outcome | 2018 |
Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Models, Biological; Neoplasms; Neutropenia; Paclitaxel; Research Design; Treatment Outcome | 2018 |
Concomitant administration of candesartan cilexetil in patients on paclitaxel and carboplatin combination therapy increases risk of severe neutropenia
.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Carboplatin; Drug Interactions; Female; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors; Severity of Illness Index; Tetrazoles; Time Factors; Treatment Outcome | 2018 |
Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neurotoxicity Syndromes; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Progression-Free Survival; Republic of Korea; Survival Rate; Treatment Outcome | 2017 |
Liposomal paclitaxel induces fewer hematopoietic and cardiovascular complications than bioequivalent doses of Taxol.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cardiovascular Diseases; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Drug Liberation; Drug Screening Assays, Antitumor; Female; Glycerol; Hematologic Diseases; Humans; Liposomes; Male; Mice; Mice, Inbred ICR; Mice, SCID; Neutropenia; Paclitaxel; Therapeutic Equivalency; Tissue Distribution | 2018 |
Five Cases of Interstitial Pneumonitis Due to Gemcitabine and Nab-Paclitaxel Combination Treatment in Pancreatic Cancer Patients.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms | 2018 |
Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Cell Line, Tumor; Cisplatin; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Herpesvirus 4, Human; Humans; Liposomes; Male; Middle Aged; Nasopharyngeal Carcinoma; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids | 2018 |
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pancreas; Sweden; Treatment Outcome | 2019 |
Combination Cisplatin-Epirubicin-Paclitaxel Therapy for Metastatic Extramammary Paget's Disease.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Genital Neoplasms, Male; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Paget Disease, Extramammary; Prognosis; Progression-Free Survival; Retrospective Studies; Scrotum; Severity of Illness Index; Thrombocytopenia; Vulvar Neoplasms | 2019 |
[Effect of Hypoalbuminemia on Severe Neutropenia Induced by Paclitaxel Monotherapy and Paclitaxel plus Ramucirumab Combination Therapy in Patients with Gastric Cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Hypoalbuminemia; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2019 |
[Clinical Experience of Patients with Metastatic Gastric Cancer Treated Using Nab-PTX plus RAM chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Neutropenia; Paclitaxel; Splenic Neoplasms; Stomach Neoplasms | 2019 |
Toxicity and prognosis in overweight and obese women with lung cancer receiving carboplatin-paclitaxel doublet chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Overdose; Female; Humans; Lung Neoplasms; Middle Aged; Neutropenia; Obesity; Overweight; Paclitaxel; Prognosis; Retrospective Studies; Risk | 2013 |
First line therapy for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fatigue; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2013 |
Effect of the weekly administration of liposome-Paclitaxel combined with s-1 on advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Liposomes; Male; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models; Treatment Outcome | 2014 |
[Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Esophagogastric Junction; Fatigue; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Pyrimidines; Receptor, ErbB-2; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab | 2014 |
[Value of postoperative radiochemotherapy for thoracic esophageal squamous cell carcinoma with lymph node metastasis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagitis; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Particle Accelerators; Postoperative Period; Retrospective Studies; Survival Rate | 2014 |
A retrospective study of paclitaxel combining nedaplatin chemotherapy for esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Paclitaxel; Retrospective Studies | 2015 |
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Platinum; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA-Binding Proteins; Female; Genetic Association Studies; Humans; Male; Middle Aged; Multidrug Resistance-Associated Proteins; NAD(P)H Dehydrogenase (Quinone); Nausea; Neoplasm Staging; Neutropenia; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Thrombocytopenia | 2014 |
Predicting the efficacy of an oral paclitaxel formulation (DHP107) through modeling and simulation.
Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents, Phytogenic; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Monte Carlo Method; Neutropenia; Paclitaxel | 2015 |
Clozapine and concomitant chemotherapy in a patient with schizophrenia and new onset esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Carboplatin; Carcinoma, Squamous Cell; Clozapine; Esophageal Neoplasms; Humans; Male; Neutropenia; Paclitaxel; Schizophrenia | 2015 |
Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bayes Theorem; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Middle Aged; Models, Biological; Neutropenia; Nonlinear Dynamics; Paclitaxel | 2015 |
Combination therapy of liposomal paclitaxel and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Female; Humans; Liposomes; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Treatment Outcome; Tumor Burden; Uterine Cervical Neoplasms | 2015 |
Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Female; Hemoglobins; Humans; Leukopenia; Logistic Models; Lung Neoplasms; Lymphopenia; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neutropenia; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Severity of Illness Index; Survival Rate; Taxoids; Thrombocytopenia | 2017 |
Effects and toxicity of neoadjuvant chemotherapy preoperative followed by adjuvant chemoradiation in small cell neurdendocrine cervical carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Doxorubicin; Etoposide; Female; Hepatic Insufficiency; Humans; Hysterectomy; Ifosfamide; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Renal Insufficiency; Thrombocytopenia; Treatment Outcome; Uterine Cervical Neoplasms; Vincristine | 2015 |
Predicting paclitaxel-induced neutropenia using the DMET platform.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Cohort Studies; Female; Humans; Male; Membrane Transport Proteins; Middle Aged; Neutropenia; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prospective Studies; Sensitivity and Specificity; Young Adult | 2015 |
[Efficacy and safety analysis of paclitaxel liposome and docetaxel for the neoadjuvant chemotherapy of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Liposomes; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 2015 |
Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Hematologic Diseases; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Radiation Dosage; Radiation Tolerance; Regression Analysis; Thoracic Vertebrae; Thrombocytopenia | 2016 |
Comparison of toxicity profile and tolerability between two standard of care paclitaxel-based adjuvant chemotherapy regimens in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Standard of Care | 2016 |
Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Creatinine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Paclitaxel; Prognosis; Retrospective Studies; Treatment Outcome; Urethral Neoplasms | 2016 |
A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cisplatin; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Prognosis; Re-Irradiation; Treatment Outcome | 2016 |
[A Patient with CA19-9-Producing Pulmonary Adenocarcinoma Who Responded to Multidisciplinary Therapy and Achieved Complete Response].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carboplatin; Chemotherapy, Adjuvant; Humans; Lung Neoplasms; Lymph Node Excision; Male; Neutropenia; Paclitaxel | 2016 |
Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Practice Patterns, Physicians'; Retrospective Studies; Young Adult | 2016 |
Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial.
Topics: Administration, Intravenous; Anemia; Antineoplastic Agents; Blood Transfusion; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Decision Support Techniques; Disease-Free Survival; Drug Costs; Female; Filgrastim; Hematologic Agents; Hospitalization; Humans; Markov Chains; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proportional Hazards Models; Randomized Controlled Trials as Topic | 2017 |
The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Administration Schedule; Female; Filgrastim; Genital Neoplasms, Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Taxoids; Young Adult | 2009 |
Outpatient management of low-risk febrile patients on paclitaxel and carboplatin for ovarian cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Fever; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Risk Assessment; Telephone | 2009 |
A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Polyethylene Glycols; Prognosis; Recombinant Proteins; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.
Topics: Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Japan; Lung Neoplasms; Neoplasm Staging; Neutropenia; Paclitaxel; Pharmacogenetics; Pneumonectomy; Proportional Hazards Models; Prospective Studies; Quality of Life; Survival; United States | 2009 |
Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Brain Neoplasms; Chemistry, Pharmaceutical; Disease Models, Animal; Drug Screening Assays, Antitumor; Glycerol; Liposomes; Male; Maximum Tolerated Dose; Models, Theoretical; Neutropenia; Paclitaxel; Pharmaceutical Vehicles; Rats; Rats, Inbred Strains; Tumor Burden | 2010 |
Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer?
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Korea; Leukocyte Count; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Prognosis; Retrospective Studies; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2010 |
Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Analysis | 2010 |
Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Doxorubicin; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Polyethylene Glycols; Recurrence; Retrospective Studies; Treatment Outcome | 2011 |
Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma.
Topics: Anemia; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Neoplasm Staging; Nervous System Diseases; Neutropenia; Ovarian Neoplasms; Paclitaxel; Survival Rate; Thrombocytopenia | 2010 |
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Platelets; Carboplatin; Cell Proliferation; Deoxycytidine; Etoposide; Female; France; Gemcitabine; Humans; Leukocyte Count; Male; Middle Aged; Models, Biological; Neutropenia; Neutrophils; Paclitaxel; Platelet Count; Prospective Studies; Risk Assessment; Risk Factors; Thrombocytopenia; Young Adult | 2010 |
Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Carboplatin; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Female; Genetic Variation; Genotype; Humans; Leukocyte Count; Leukopenia; Neutropenia; Ovarian Neoplasms; Paclitaxel; Pharmacogenetics; Phenotype; Prospective Studies; Risk Factors | 2011 |
Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2012 |
Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retreatment; Retrospective Studies; Thrombocytopenia | 2012 |
[Results of chemotherapy for gynecologic cancer patients in ambulatory care].
Topics: Ambulatory Care; Ambulatory Care Facilities; Anemia, Hypochromic; Antineoplastic Agents; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Hospitalization; Humans; Middle Aged; Neutropenia; Outpatients; Ovarian Neoplasms; Paclitaxel; Quality of Life; Russia; Thrombocytopenia; Treatment Outcome; Uterine Cervical Neoplasms | 2011 |
Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Costs and Cost Analysis; Cyclophosphamide; Databases, Factual; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Health Care Costs; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors; Taxoids | 2012 |
[Support of hematological homeostasis during chemotherapy with taxanes].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caproates; Docetaxel; Female; Fever; Follow-Up Studies; Homeostasis; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Protective Agents; Severity of Illness Index; Stomach Neoplasms; Taxoids; Tongue Neoplasms | 2011 |
Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
Topics: Aged; Algorithms; Antineoplastic Agents, Phytogenic; Computer Simulation; Drug Monitoring; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Neutropenia; Paclitaxel | 2012 |
Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Cause of Death; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fever; Fluorouracil; Humans; Malaysia; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors; Taxoids | 2012 |
Pegfilgrastim: the promise of pegylation fulfilled.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2003 |
Dosing study seen as victory for clinical trials, mathematical models.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Models, Theoretical; Neutropenia; Paclitaxel; Recombinant Proteins; Regression Analysis; Research Design; Survival Analysis; Treatment Outcome | 2003 |
Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxel.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Diarrhea; Docetaxel; Drug Hypersensitivity; Feasibility Studies; Female; Humans; Male; Middle Aged; Nausea; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Patient Compliance; Prospective Studies; Severity of Illness Index; Taxoids; Treatment Outcome; Vomiting | 2003 |
[Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Taxoids; Thrombocytopenia; Uterine Cervical Neoplasms | 2003 |
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Data Interpretation, Statistical; Endpoint Determination; Head and Neck Neoplasms; Humans; Ifosfamide; Mesna; Neutropenia; Paclitaxel; Reproducibility of Results; Survival; Taxoids | 2003 |
A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Rate; Thrombocytopenia; Topotecan; Treatment Failure | 2003 |
Granulocyte-macrophage colony stimulating factor prior to chemotherapy for advanced epithelial ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Probability; Prognosis; Prospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2003 |
Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Taxoids; Treatment Outcome | 2004 |
Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Fever; Genital Neoplasms, Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Taxoids | 2004 |
Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases | 2003 |
[Paclitaxel, ifosfamide, nedaplatin (TIN) for patients with metastatic urothelial cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Paclitaxel; Survival Rate; Thrombocytopenia; Urologic Neoplasms | 2004 |
Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Evaluation; Female; Follow-Up Studies; Humans; Life Tables; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2004 |
Treatment of advanced non-small-cell lung cancer in special populations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Humans; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Neutropenia; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Erythropoietin; Female; Humans; Incidence; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Skin Diseases; Taxoids | 2005 |
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration.
Topics: Animals; Area Under Curve; Azure Stains; Bone Marrow Cells; Chromosome Aberrations; Chromosome Painting; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Etoposide; Infusions, Intravenous; Macaca mulatta; Neutropenia; Paclitaxel; Thiotepa | 2005 |
[Neutropenia induced by taxoids and its control with granulocyte colony-stimulating factor].
Topics: Antineoplastic Agents; Docetaxel; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Neutropenia; Paclitaxel; Recombinant Proteins; Retrospective Studies; Taxoids | 2005 |
[Feasibility study of weekly paclitaxel as second-line chemotherapy against 5-FU-refractory gastric carcinoma].
Topics: Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Fluorouracil; Humans; Leukopenia; Neutropenia; Paclitaxel; Stomach Neoplasms; Survival Rate | 2005 |
A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Maximum Tolerated Dose; Neutropenia; Paclitaxel; Platinum; Survival Rate; Time Factors | 2005 |
Abraxane induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Bilirubin; Breast Neoplasms; Female; Humans; Liver; Liver Neoplasms; Middle Aged; Mucositis; Nausea; Neutropenia; Paclitaxel | 2006 |
Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Enterobacteriaceae Infections; Enterococcus; Escherichia coli; Escherichia coli Infections; Female; Fever; Humans; Klebsiella; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2006 |
[Combination chemotherapy with carboplatin and weekly Paclitaxel in patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Retrospective Studies; Survival Rate | 2006 |
Albumin-bound Paclitaxel: in metastatic breast cancer.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Glycerol; Humans; Nanostructures; Neoplasm Metastasis; Neutropenia; Paclitaxel; Treatment Outcome | 2006 |
Albumin-bound Paclitaxel in metastatic breast cancer: viewpoints.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Glycerol; Humans; Nanostructures; Neoplasm Metastasis; Neutropenia; Paclitaxel; Treatment Outcome | 2006 |
[Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for relapsed or refractory germ cell cancer].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Ifosfamide; Male; Neoplasms, Germ Cell and Embryonal; Neutropenia; Organoplatinum Compounds; Paclitaxel; Salvage Therapy; Testicular Neoplasms; Thrombocytopenia | 2006 |
[A case of non-curatively resected gastric cancer successfully treated over 3 years with biweekly paclitaxel therapy].
Topics: Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Gastrectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Neutropenia; Paclitaxel; Stomach Neoplasms; Survivors | 2006 |
[Adjuvant chemotherapy of paclitaxel plus carboplatin in uterine corpus cancer--comparison with cisplatin, adriamycin plus cyclophosphamide].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Hysterectomy; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia; Uterine Neoplasms | 2006 |
Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colony-Stimulating Factors; Docetaxel; Epirubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2006 |
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Genotype; Humans; Neutropenia; Organic Anion Transporters; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Genetic | 2006 |
Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Drug Interactions; Etoposide; Female; Humans; Liver; Male; Middle Aged; Models, Theoretical; Neutropenia; Neutrophils; Paclitaxel; Sex Characteristics; Taxoids; Topotecan | 2006 |
Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Pneumonia, Pneumocystis; Polyethylene Glycols; Prednisone; Recombinant Proteins; Trimethoprim, Sulfamethoxazole Drug Combination | 2006 |
Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2006 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
[Good response in ARDS treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Drug Administration Schedule; Drug Combinations; Glycine; Humans; Male; Neutropenia; Oxonic Acid; Paclitaxel; Respiratory Distress Syndrome; Serine Proteinase Inhibitors; Sulfonamides; Tegafur | 2007 |
[Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Mastectomy; Middle Aged; Nausea; Neutropenia; Paclitaxel; Postoperative Period; Retrospective Studies; Taxoids | 2007 |
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Disease Progression; Drug Design; Europe; Female; Humans; Kinetics; Neutropenia; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Thrombocytopenia; Treatment Outcome | 2007 |
The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2008 |
Measuring the cost of chemotherapy is important, but it is not enough.
Topics: Antineoplastic Agents; Breast Neoplasms; Complementary Therapies; Cost of Illness; Cost-Benefit Analysis; Docetaxel; Drug Costs; Humans; Neutropenia; Paclitaxel; Quality of Life; Quality-Adjusted Life Years; Survival Analysis; Taxoids; Therapies, Investigational | 2008 |
Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Japan; Mastectomy; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2008 |
Paclitaxel: what schedule? What dose?
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Neutropenia; Paclitaxel | 1994 |
Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol.
Topics: Administration, Oral; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carboplatin; Chi-Square Distribution; Ciprofloxacin; Cisplatin; Costs and Cost Analysis; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Leukocyte Count; Middle Aged; Neutropenia; Neutrophils; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 1994 |
Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Specimen Collection; Breast Neoplasms; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platelet Count; Thrombocytopenia; Transplantation, Homologous | 1995 |
What you need to know about Taxol.
Topics: Adenocarcinoma; Drug Hypersensitivity; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1993 |
Primary therapy of Waldenstrom's macroglobulinemia with paclitaxel.
Topics: Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Waldenstrom Macroglobulinemia | 1994 |
[Toxicity studies of paclitaxel. (I)--Single dose intravenous toxicity in rats].
Topics: Alopecia; Animals; Atrophy; Bone Marrow; Female; Injections, Intravenous; Male; Neutropenia; Paclitaxel; Rats; Rats, Sprague-Dawley; Spermatogenesis; Spleen; Testis; Thymus Gland | 1994 |
Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cause of Death; Female; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Neutrophils; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Remission Induction; Survival Rate; Vinblastine; Vinorelbine; Vomiting | 1996 |
Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Ventricular Function | 1996 |
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Etoposide; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Pilot Projects; Remission Induction; Sarcoma; Thrombocytopenia | 1996 |
Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Doxorubicin; Female; Heart; Heart Failure; Humans; Infusions, Intravenous; Middle Aged; Muscular Diseases; Nausea; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pain; Paresthesia; Remission Induction; Stroke Volume; Ventricular Function, Left; Vomiting | 1996 |
Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Ascites; Breast Neoplasms; Docetaxel; Edema; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pleural Effusion; Taxoids; Treatment Failure; Treatment Outcome | 1997 |
[Advance through research].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy; Humans; Neutropenia; Paclitaxel; Research; Taxoids | 1994 |
Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Carcinoma; Cause of Death; Drug Hypersensitivity; Endometrial Neoplasms; Female; Fever; Genital Neoplasms, Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Remission Induction; Retrospective Studies; Sepsis; Thrombocytopenia; Treatment Outcome | 1997 |
Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma; Cisplatin; Confidence Intervals; Disease Progression; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Remission Induction; Risk Factors; Survival Rate; Thrombocytopenia; Treatment Failure; Vinblastine; Vinorelbine | 1998 |
A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Bone Marrow; Breast Neoplasms; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; Leukocyte Count; Models, Theoretical; Neutropenia; Neutrophils; Ovarian Neoplasms; Paclitaxel; Pharmacokinetics; Time Factors | 1998 |
[Neutropenic enterocolitis].
Topics: Antineoplastic Agents, Phytogenic; Biopsy; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Enterocolitis, Pseudomembranous; Female; Humans; Intestinal Mucosa; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Palliative Care; Radiation Injuries; Sigmoidoscopy | 1998 |
Docetaxel is a potent cytotoxic drug in the treatment of advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Microtubules; Middle Aged; Mitosis; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Tubulin | 1998 |
Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 1998 |
Continual reassessment methods in phase I trials of the combination of two drugs in oncology.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Camptothecin; Clinical Trials, Phase I as Topic; Computer Simulation; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Humans; Irinotecan; Likelihood Functions; Neoplasms; Neutropenia; Paclitaxel; Retrospective Studies; Taxoids | 1999 |
A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cells, Cultured; Culture Media, Serum-Free; Cyclophosphamide; Dendritic Cells; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-4; Leukapheresis; Leukocyte Count; Lymphocyte Culture Test, Mixed; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neutropenia; Paclitaxel; Taxoids | 1999 |
A novel combination of paclitaxel, etoposide, and cyclophosphamide for stem cell mobilization and tumor cytoreduction in ovarian cancer.
Topics: Alopecia; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Carcinoma, Papillary; Cyclophosphamide; Endometrial Neoplasms; Etoposide; Female; Fever; Hematopoietic Stem Cell Mobilization; Humans; Klebsiella Infections; Leukapheresis; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Serous Membrane; Taxoids | 2000 |
Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Squamous Cell; Docetaxel; Enterocolitis; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Taxoids; Tomography, X-Ray Computed | 2000 |
The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Rate; Ventricular Dysfunction, Left | 2000 |
Docetaxel-induced lymphopenia in patients with solid tumors: a prospective phenotypic analysis.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Female; Humans; Immunophenotyping; Infections; Lymphocyte Count; Lymphocyte Subsets; Lymphocytes; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Neutrophils; Paclitaxel; Prospective Studies; Taxoids | 2000 |
Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Cystadenocarcinoma, Papillary; Female; Humans; Kidney Failure, Chronic; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Renal Dialysis; Thrombocytopenia | 2001 |
[Effect of G-CSF (nartograstim) on neutropenia (leukopenia) induced by taxane in metastatic breast cancer--time-course changes in neutrophil and leukocyte counts].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Neutropenia; Neutrophils; Paclitaxel; Retrospective Studies; Taxoids | 2001 |
Reversal of paclitaxel induced neutropenia by Withania somnifera in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Granulocyte-Macrophage Colony-Stimulating Factor; India; Male; Mice; Neutropenia; Paclitaxel; Phytotherapy; Plant Extracts; Plants, Medicinal | 2001 |
Paclitaxel and carboplatin as outpatient therapy for stage III and IV epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel | 2001 |
A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel | 2001 |
Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Blood Cell Count; Bone Marrow Cells; Erythroid Precursor Cells; Liposomes; Male; Neutropenia; Neutrophils; Paclitaxel; Rats; Rats, Sprague-Dawley | 2001 |
Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Therapy, Combination; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Infection Control; Infections; Inflammation; Melphalan; Middle Aged; Mitoxantrone; Mucous Membrane; Multivariate Analysis; Neutropenia; Paclitaxel; Patient Selection; Retrospective Studies; Risk; Taxoids; Thiotepa; Transplantation Conditioning | 2001 |
Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Dose-Response Relationship, Drug; Female; Glycerol; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Pharmaceutical Vehicles; Surface-Active Agents | 2002 |
Treatment side effects. Case 2. Toxic, epidermal, necrolysis-like reaction associated with docetaxel chemotherapy.
Topics: Adult; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Eruptions; Female; Humans; Lymphoma, Non-Hodgkin; Neutropenia; Paclitaxel; Salvage Therapy; Taxoids; Treatment Outcome | 2002 |
Taxol: twenty years later, the story unfolds.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1991 |
A phase II trial of taxol in metastatic melanoma.
Topics: Adult; Alkaloids; Antineoplastic Agents, Phytogenic; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1990 |
Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Evaluation; Drug Hypersensitivity; Humans; Infusions, Intravenous; Kinetics; Melanoma; Neoplasms; Nervous System Diseases; Neutropenia; Paclitaxel | 1987 |